



# HHS Public Access

Author manuscript

*Circulation*. Author manuscript; available in PMC 2016 July 25.

Published in final edited form as:

*Circulation*. 2015 November 3; 132(18 Suppl 2): S465–S482. doi:10.1161/CIR.0000000000000262.

## Part 8: Post–Cardiac Arrest Care:

### 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Clifton W. Callaway [Chair], Michael W. Donnino, Ericka L. Fink, Romergryko G. Geocadin, Eyal Golan, Karl B. Kern, Marion Leary, William J. Meurer, Mary Ann Peberdy, Trevonne M. Thompson, and Janice L. Zimmerman

#### Keywords

cardiac arrest; drug; imaging; moderate hypothermia

#### Introduction

The recommendations in this *2015 American Heart Association (AHA) Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care* are based on an extensive evidence review process that was begun by the International Liaison Committee on Resuscitation (ILCOR) after the publication of the *2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations*<sup>1,2</sup> and was completed in February 2015.<sup>3,4</sup>

In this in-depth evidence review process, ILCOR examined topics and then generated a prioritized list of questions for systematic review. Questions were first formulated in PICO (population, intervention, comparator, outcome) format,<sup>5</sup> and then search strategies and inclusion and exclusion criteria were defined and a search for relevant articles was performed. The evidence was evaluated by the ILCOR task forces by using the standardized methodological approach proposed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group.<sup>6</sup>

The quality of the evidence was categorized based on the study methodologies and the 5 core GRADE domains of risk of bias, inconsistency, indirectness, imprecision, and other considerations (including publication bias). Then, where possible, consensus-based treatment recommendations were created.

To create this 2015 Guidelines Update, the AHA formed 15 writing groups, with careful attention to manage conflicts of interest, to assess the ILCOR treatment recommendations and to write AHA treatment recommendations by using the AHA Class of Recommendation

---

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

The online version of this article, along with updated information and services, is located on the World Wide Web at: [http://circ.ahajournals.org/content/132/18\\_suppl\\_2/S465](http://circ.ahajournals.org/content/132/18_suppl_2/S465)

(COR) and Level of Evidence (LOE) system. The recommendations made in the Guidelines are informed by the ILCOR recommendations and GRADE classification, in the context of the delivery of medical care in North America. The AHA writing group made new recommendations only on topics specifically reviewed by ILCOR in 2015. This chapter delineates instances where the AHA writing group developed recommendations that are significantly stronger or weaker than the ILCOR statements. In the online version of this publication, live links are provided so the reader can connect directly to the systematic reviews on the Scientific Evidence Evaluation and Review System (SEERS) website. These links are indicated by a combination of letters and numbers (eg, ALS 790). We encourage readers to use the links and review the evidence and appendixes, including the GRADE tables.

This update uses the newest AHA COR and LOE classification system, which contains modifications of the Class III recommendation and introduces LOE B-R (randomized studies) and B-NR (nonrandomized studies) as well as LOE C-LD (limited data) and LOE C-EO (consensus of expert opinion). All recommendations made in this 2015 Guidelines Update, as well as in the 2010 Guidelines for post–cardiac arrest care, are listed in the Appendix. For further information, see “Part 2: Evidence Evaluation and Management of Conflicts of Interest” in this 2015 Guidelines Update.

### Overview of Post–Cardiac Arrest Care

The 2010 Guidelines emphasized that cardiac arrest can result from many different diseases. Regardless of cause, the hypoxemia, ischemia, and reperfusion that occur during cardiac arrest and resuscitation may cause damage to multiple organ systems.<sup>7</sup> The severity of damage can vary widely among patients and among organ systems within individual patients. Therefore, effective post–cardiac arrest care consists of identification and treatment of the precipitating cause of cardiac arrest combined with the assessment and mitigation of ischemia-reperfusion injury to multiple organ systems. Care must be tailored to the particular disease and dysfunction that affect each patient. Therefore, individual patients may require few, many, or all of the specific interventions discussed in the remainder of this Part.

## Cardiovascular Care

### Acute Cardiovascular Interventions [ACS 340](#), [ACS 885](#)

The 2010 Guidelines recommended obtaining a 12-lead electrocardiogram (ECG) as soon as possible after return of spontaneous circulation (ROSC) to identify if acute ST elevation is present, and to perform urgent coronary angiography with prompt recanalization of any infarct-related artery in select post–cardiac arrest patients in whom ST-segment elevation was identified. Acute coronary syndromes are a common etiology for out-of-hospital cardiac arrest (OHCA) in adults with no obvious extracardiac cause of arrest<sup>8–10</sup> and also can precipitate some in-hospital cardiac arrest. In series in which consecutive post–cardiac arrest patients with suspected cardiovascular cause were taken to coronary angiography, a coronary artery lesion amenable to emergency treatment was found in 96% of patients with ST elevation and in 58% of patients without ST elevation.<sup>10</sup>

The 2015 ILCOR systematic review examined immediate coronary angiography for patients after cardiac arrest.

**2015 Evidence Summary**—Numerous observational studies evaluate the relationship between coronary angiography, survival, and functional outcome in post–cardiac arrest patients, but there are no prospective randomized trials evaluating an interventional strategy in postarrest patients. The timing of immediate coronary angiography was defined in various ways in different studies, but all studies considered immediate angiography as a procedure performed on the same day as the cardiac arrest, as opposed to later in the hospital stay. Fifteen observational studies reported improved survival to hospital discharge associated with emergency coronary angiography in patients with ST elevation after cardiac arrest.<sup>11–25</sup> Nine observational studies showed improved neurologically favorable outcome associated with emergency coronary angiography in patients with ST elevation after cardiac arrest.<sup>11–13,16,18–21,23</sup>

Fewer data are available to evaluate coronary angiography in patients without ST elevation on the initial ECG. Two observational studies reported improved survival to hospital discharge and improved neurologically favorable outcome associated with emergency coronary angiography in patients without ST elevation on initial ECG.<sup>11,16</sup>

**2015 Recommendations—Updated**—Coronary angiography should be performed emergently (rather than later in the hospital stay or not at all) for OHCA patients with suspected cardiac etiology of arrest and ST elevation on ECG (Class I, LOE B-NR).

Emergency coronary angiography is reasonable for select (eg, electrically or hemodynamically unstable) adult patients who are comatose after OHCA of suspected cardiac origin but without ST elevation on ECG (Class IIa, LOE B-NR).

Coronary angiography is reasonable in post–cardiac arrest patients for whom coronary angiography is indicated regardless of whether the patient is comatose or awake (Class IIa, LOE C-LD).

Early invasive approaches are preferred for patients with ST-segment elevation myocardial infarction (STEMI), making these recommendations for post–cardiac arrest patients consistent with global recommendations for all patients with STEMI.<sup>26</sup> Early invasive approaches also are suggested for treatment of select post–cardiac arrest patients with acute coronary syndromes without ST elevation. Considerations for selecting patients are complex and may consider factors such as hemodynamic or electrical instability as well as comorbidities, evidence of ongoing ischemia, and other patient characteristics.<sup>27</sup> Knowledge of coronary anatomy and opportunity for placement of temporary support devices are other potential benefits derived from early catheterization. Therefore, these recommendations for post–cardiac arrest care are consistent with recommendations for all patients with non-STEMI acute coronary syndromes. Both the European Society of Cardiology and the combined entity of the American College of Cardiology Foundation and the AHA have published STEMI guidelines recommending immediate coronary angiography, and percutaneous coronary intervention when indicated, for resuscitated OHCA patients whose

ECGs show STEMI.<sup>26,28</sup> None of these guidelines recommended different treatment of patients based on the initial cardiac arrest rhythm (ventricular fibrillation [VF] or non-VF).

Previous consensus statements have discussed how public reporting of postprocedure death creates an incentive to avoid emergency coronary angiography in comatose patients who are at higher risk of death as a consequence of poor neurologic recovery.<sup>29</sup> However, the probability of neurologic recovery cannot be determined reliably at the time that emergency cardiovascular interventions are performed (see Prognostication of Outcome section in this Part). Therefore, the best care for the patient requires separation of decisions about cardiovascular intervention from assessment of neurologic prognosis.

### Hemodynamic Goals<sup>ALS 570</sup>

Post-cardiac arrest patients are often hemodynamically unstable, which can occur for multiple reasons that include the underlying etiology of the arrest as well as the ischemia-reperfusion injury from the arrest. Management of these patients can be challenging, and optimal hemodynamic goals remain undefined. In 2015, ILCOR evaluated the optimal hemodynamic targets in post-cardiac arrest patients, primarily considering blood pressure goals.

**2015 Evidence Summary**—There are several observational studies evaluating the relationship between blood pressure and outcome in post-cardiac arrest patients, but there are no interventional studies targeting blood pressure in isolation and no trials evaluating one specific strategy for improving blood pressure over another (ie, fluids, vasopressors). Observational studies found that post-cardiac arrest systolic blood pressure less than 90 mm Hg<sup>30,31</sup> or greater than 100 mm Hg<sup>32</sup> was associated with higher mortality and diminished functional recovery. One observational study found that mean arterial pressure (MAP) greater than 100 mm Hg during 2 hours after ROSC was associated with better neurologic recovery at hospital discharge.<sup>33</sup> Another observational study found that survivors, compared with nonsurvivors, had higher MAP at 1 hour (96 versus 84 mm Hg) and at 6 hours (96 versus 90 mm Hg).<sup>34</sup>

While no studies evaluated blood pressure in isolation, several before-and-after studies implemented bundles of care that included blood pressure goals. In these studies, the individual effect of blood pressure was impossible to separate from the effects of the remainder of the bundle. One bundle with a MAP target of greater than 80 mm Hg improved mortality and neurologic outcome at hospital discharge.<sup>35</sup> One bundle with a goal of MAP over 75 mm Hg found no change in functional recovery at hospital discharge.<sup>36</sup> One bundle with MAP greater than 65 mm Hg increased survival to hospital discharge, with a favorable neurologic outcome at 1 year.<sup>37</sup> Another bundle with a goal MAP greater than 65 mm Hg within 6 hours found no change in in-hospital mortality or functional recovery at hospital discharge.<sup>38</sup>

**2015 Recommendation—New**—Avoiding and immediately correcting hypotension (systolic blood pressure less than 90 mm Hg, MAP less than 65 mm Hg) during postresuscitation care may be reasonable (Class IIb, LOE C-LD).

A specific MAP or systolic blood pressure that should be targeted as part of the bundle of postresuscitation interventions could not be identified, although published protocols targeted MAP goals of greater than 65 mm Hg to greater than 80 mm Hg. Moreover, identifying an optimal MAP goal for the overall patient population may be complicated by individual patient variability, because baseline blood pressures vary among patients. The true optimal blood pressure would be that which allows for optimal organ and brain perfusion, and different patients and different organs may have different optimal pressures.

Targets for other hemodynamic or perfusion measures (such as cardiac output, mixed/central venous oxygen saturation, and urine output) remain undefined in post-cardiac arrest patients. The systematic reviews did not identify specific targets for other variables, and individual goals likely vary based on patient-specific comorbidities and underlying physiology. In the absence of evidence for specific targets, the writing group made no recommendations to target any hemodynamic goals other than those that would be used for other critically ill patients.

## Targeted Temperature Management

The 2010 Guidelines strongly advised induced hypothermia (32°C to 34°C) for the subgroup of patients with out-of-hospital VF/pulseless ventricular tachycardia (pVT) cardiac arrest and post-ROSC coma (the absence of purposeful movements), and encouraged that induced hypothermia be considered for most other comatose patients after cardiac arrest. Precise duration and optimal temperature targets were unknown, and the Guidelines recommended 12 to 24 hours at 32°C to 34°C based on the regimens studied in prior trials. The 2015 ILCOR systematic review identified multiple new randomized controlled trials testing different target temperatures and different timing for initiation of temperature control after cardiac arrest.<sup>39</sup> Reflecting that a variety of temperature targets are now used, the term *targeted temperature management* (TTM) has been adopted to refer to induced hypothermia as well as to active control of temperature at any target.

### Induced Hypothermia [ALS 790](#), [ALS 791](#)

**2015 Evidence Summary**—For patients with VF/pVT OHCA, combined outcome data from 1 randomized and 1 quasi-randomized clinical trial reported increased survival and increased functional recovery with induced hypothermia to 32°C to 34°C.<sup>40,41</sup>

For patients with OHCA and nonshockable rhythms, observational data were conflicting and no randomized data were available. Three observational studies found no difference in neurologic outcome at hospital discharge in patients treated with induced hypothermia.<sup>42–44</sup> One study reported an increase in poor neurologic outcome at hospital discharge; however, the analysis of this study was confounded perhaps most notably by lack of information on whether analyzed patients were eligible for induced hypothermia (ie, unknown if patients were following commands).<sup>45</sup> One study reported reduced mortality at 6 months with induced hypothermia.<sup>43</sup>

For patients with in-hospital cardiac arrest, no randomized data were available. One observational study found no association between induced hypothermia and survival or

functionally favorable status at hospital discharge. However, the analysis of this study was also confounded by multiple factors, including the lack of information on which patients were comatose and, therefore, potential candidates for induced hypothermia.<sup>46</sup>

One well-conducted randomized controlled trial found that neurologic outcomes and survival at 6 months after OHCA were not superior when temperature was controlled at 36°C versus 33°C.<sup>47</sup> Both arms of this trial involved a form of TTM as opposed to no TTM.

There are no direct comparisons of different durations of TTM in post-cardiac arrest patients. The largest trials and studies of TTM maintained temperatures for 24 hours<sup>40</sup> or 28 hours<sup>47</sup> followed by a gradual (approximately 0.25°C/hour) return to normothermia.

**2015 Recommendations—Updated**—We recommend that comatose (ie, lack of meaningful response to verbal commands) adult patients with ROSC after cardiac arrest have TTM (Class I, LOE B-R for VF/pVT OHCA; Class I, LOE C-EO for non-VF/pVT (ie, “nonshockable”) and in-hospital cardiac arrest).

We recommend selecting and maintaining a constant temperature between 32°C and 36°C during TTM (Class I, LOE B-R).

In making these strong recommendations, the writing group was influenced by the recent clinical trial data enrolling patients with all rhythms, the rarity of adverse effects in trials, the high neurologic morbidity and mortality without any specific interventions, and the preponderance of data suggesting that temperature is an important variable for neurologic recovery. Of note, there are essentially no patients for whom temperature control somewhere in the range between 32°C and 36°C is contraindicated. Specific features of the patient may favor selection of one temperature over another for TTM. Higher temperatures might be preferred in patients for whom lower temperatures convey some risk (eg, bleeding),<sup>48,49</sup> and lower temperatures might be preferred when patients have clinical features that are worsened at higher temperatures (eg, seizures, cerebral edema).<sup>50–52</sup> Therefore, all patients in whom intensive care is continued are eligible. The initial temperature of the patient may influence selection of the temperature for TTM. For example, those who present at the lower end of the TTM range might be maintained at that lower temperature (as opposed to warming them to a higher target). Alternatively, passive warming to a maximum temperature of 36°C might be acceptable as well. Of note is that the recent randomized trial did not use active warming for the 36°C group.<sup>47</sup> Therefore, while it is stated that choosing a temperature within the 32°C to 36°C range is acceptable, actively or rapidly warming patients is not suggested. Conversely, patients who present on the higher end of the TTM range might be kept at 36°C without much additional effort. Providers should note that allowing patients to warm to temperatures above 36°C would be more akin to the control group of the earlier trials and not consistent with the current TTM recommendations.

The recommendations for TTM for nonshockable rhythms and for patients following in-hospital arrest are stronger than those made in 2015 by ILCOR<sup>3,4</sup> and are stronger than the recommendations in “Part 9: Post-Cardiac Arrest Care” in the 2010 Guidelines. The writing group felt that the option for TTM at 36°C diminished theoretical concerns about side

effects of TTM for these populations. In addition, the writing group was influenced by the high rate of neurologic morbidity in historical cohorts that did not use TTM.

It is reasonable that TTM be maintained for at least 24 hours after achieving target temperature (Class IIa, LOE C-EO).

Even if the selected target temperature is not achieved during this time frame, clinicians should still try to control temperature for at least 24 hours after cardiac arrest. Temperature sensitivity of the brain after cardiac arrest may continue for as long as brain dysfunction (ie, coma) is present, making the upper limit of duration for temperature management unknown. The duration of at least 24 hours was used in 2 of the largest trials, although there are no comparative data for this duration. For these reasons, 24 hours was selected as the minimum recommended time for TTM.

### Hypothermia in the Prehospital Setting<sup>ALS 802</sup>

The initiation of hypothermia has been popularized in the pre-hospital setting, though the original studies showing efficacy from induced hypothermia did not systematically study the prehospital setting. A logical assumption for the widespread implementation of this practice stemmed from the concept that earlier provision of an effective intervention would be more beneficial. However, induction of prehospital hypothermia was not extensively evaluated by large-scale randomized trials in 2010. Since that time, a number of additional trials have been published, including at least 1 large-scale investigation. In 2015, ILCOR examined the question of whether early provision of TTM was beneficial, with a focus on the prehospital period.

**2015 Evidence Summary**—Five randomized controlled trials<sup>53–57</sup> compared the post-ROSC use of cold intravenous fluids to induce hypothermia to no fluids. One trial compared cold intravenous fluid during resuscitation to no cooling,<sup>58</sup> and another trial compared intra-arrest intranasal cooling to no cooling.<sup>59</sup> When cooling maneuvers were initiated in the prehospital setting, neither survival nor neurologic recovery differed for any of these trials alone or when combined in a meta-analysis. One trial found an increase in pulmonary edema and re-arrest among patients treated with a goal of prehospital infusion of 2 L of cold fluids.<sup>57</sup>

**2015 Recommendation—New**—We recommend **against** the routine prehospital cooling of patients after ROSC with rapid infusion of cold intravenous fluids (Class III: No Benefit, LOE A).

During the past few years, infusion of cold intravenous fluids has become a popular prehospital intervention that may influence the system of care. Initiation of a temperature management strategy en route to the hospital may increase the probability that temperature management continues during the hospitalization. Adverse effects of the rapid infusion of cold intravenous fluids in the prehospital setting must be weighed against this potential positive effect of earlier intervention. Current evidence indicates that there is no direct patient benefit from these interventions and that the intravenous fluid administration in the prehospital setting may have some potential harm, albeit with no increase in overall

mortality. Whether different methods or devices for temperature control outside of the hospital are beneficial is unknown.

### **Avoidance of Hyperthermia**<sup>ALS 879</sup>

After the completion of TTM for a set duration (such as 24 hours), the optimal approach to subsequent temperature management remains unknown. In 2015, the ILCOR systematic review evaluated both the approach to hyperthermia on presentation (before initiation of TTM) and after rewarming. The treatment recommendation to maintain a targeted temperature between 32°C and 36°C for postarrest patients will prevent early hyperthermia. Therefore, treatment recommendations for the avoidance of hyperthermia focus on the post-rewarming period.

**2015 Evidence Summary**—Observational studies consistently report that fever in the post-cardiac arrest patient who is not treated with TTM is associated with poor outcome.<sup>60–64</sup>

After rewarming to normothermia from TTM, many studies have noted that fever occurs in a significant proportion of patients.<sup>64–71</sup> Occurrence of hyperthermia during the first few days after cardiac arrest was associated with worse outcome in 2 studies<sup>70,71</sup> but not in others.<sup>64–69</sup>

**2015 Recommendation—New**—It may be reasonable to actively prevent fever in comatose patients after TTM (Class IIb, LOE C-LD).

Fever will not occur during the first 24 to 48 hours after cardiac arrest when patients are treated with TTM. Though the evidence that supports avoiding hyperthermia is weak in postarrest patients, the intervention is relatively benign. In addition, fever is associated with worsened neurologic injury in comatose patients receiving intensive care for other conditions.<sup>72,73</sup> Therefore, the recommendation of the avoidance of fever is based on expert opinion that a relatively benign procedure is reasonable to perform in the face of a potential for worsening ischemic brain injury. The simplest method to accomplish prolonged hyperthermia prevention may be to leave the devices or strategies used for TTM in place.

### **Other Neurologic Care**

The 2010 Guidelines emphasized advanced neurocritical care for patients who have brain injury after cardiac arrest, including electroencephalography (EEG) for detection of seizures, and prompt treatment of seizures. The 2015 ILCOR systematic review considered detection and treatment of seizures.

### **Seizure Management**<sup>ALS 868, ALS 431</sup>

**2015 Evidence Summary**—The prevalence of seizures, nonconvulsive status epilepticus, and other epileptiform activity among patients who are comatose after cardiac arrest is estimated to be 12% to 22%.<sup>74–76</sup> Nonconvulsive status epilepticus may be a reason that patients are not awakening from coma. Three case series looked at 47 post-cardiac



arrest patients who were treated for seizures or status epilepticus and found that only 1 patient survived with good neurologic function.<sup>77–79</sup>

Available evidence does not support prophylactic administration of anticonvulsant drugs. Two randomized clinical trials comparing anticonvulsants (thiopental<sup>80</sup> in one study and diazepam<sup>74</sup> in the other study) to placebo found no difference in any outcome when these drugs were administered shortly after ROSC. In addition, 1 nonrandomized clinical trial with historic controls did not find outcome differences when a combination of thiopental and phenobarbital<sup>81</sup> was provided after ROSC.

Prolonged epileptiform discharges are associated with secondary brain injury in other situations, making detection and treatment of nonconvulsive status epilepticus a priority.<sup>82</sup> However, there are no direct comparative studies in post–cardiac arrest patients of treating seizures versus not treating seizures. The 2015 ILCOR systematic review did not identify any evidence that 1 specific drug or combination of drugs was superior for treatment of epileptiform activity after cardiac arrest.

**2015 Recommendations—Updated**—An EEG for the diagnosis of seizure should be promptly performed and interpreted, and then should be monitored frequently or continuously in comatose patients after ROSC (Class I, LOE C-LD).

The same anticonvulsant regimens for the treatment of status epilepticus caused by other etiologies may be considered after cardiac arrest (Class IIb, LOE C-LD).

## Respiratory Care

The 2010 Guidelines emphasized the identification of pulmonary dysfunction after cardiac arrest. The 2015 ILCOR systematic review evaluated whether a particular strategy of ventilator management should be employed for postarrest patients, with a specific focus on a target range for  $Paco_2$ .

### Ventilation<sup>ALS 571</sup>

**2015 Evidence Summary**—Systematic reviews examined whether ventilation to achieve and maintain a particular  $Paco_2$  was associated with improved outcome. Two observational studies<sup>83,84</sup> found hypocapnia to be associated with a worse neurologic outcome, and 1 observational study found hypocapnia was associated with failure to be discharged home.<sup>85</sup> Observational studies did not find any consistent association between hypercapnia and outcome.<sup>83–86</sup>

**2015 Recommendation—Updated**—Maintaining the  $Paco_2$  within a normal physiological range, taking into account any temperature correction, may be reasonable (Class IIb, LOE B-NR).

Normocarbica (end-tidal  $CO_2$  30–40 mm Hg or  $Paco_2$  35–45 mm Hg) may be a reasonable goal unless patient factors prompt more individualized treatment. Other  $Paco_2$  targets may be tolerated for specific patients. For example, a higher  $Paco_2$  may be permissible in patients with acute lung injury or high airway pressures. Likewise, mild hypocapnia might be useful

as a temporizing measure when treating cerebral edema, but hyperventilation might cause cerebral vasoconstriction. The need to avoid potential hyperventilation-induced cerebral vasoconstriction needs to be weighed against the correction of metabolic acidosis by hyperventilation. Providers should note that when patient temperature is below normal, laboratory values reported for  $Paco_2$  might be higher than the actual values in the patient.

### Oxygenation<sup>ALS 448</sup>

Previous guidelines suggested that the optimal titration of supplementary oxygen targets avoidance of prolonged hyperoxia. Episodes of hypoxia that can add to organ injury should also be prevented.

**2015 Evidence Summary**—The systematic review identified recent observational studies suggesting that excessively high arterial oxygen concentrations (hyperoxia) may harm various organs or worsen outcomes.<sup>87–89</sup> Other studies did not confirm this finding.<sup>83,86,90–92</sup> One small randomized trial comparing 30% inspired oxygen for 60 minutes after ROSC versus 100% inspired oxygen for 60 minutes after ROSC found no difference in either survival to hospital discharge or survival with favorable neurologic outcome.<sup>93</sup> Most studies defined hypoxia as  $Pao_2$  less than 60 mm Hg, and hyperoxia as a  $Pao_2$  greater than 300 mm Hg. However, the optimum upper and lower limits of  $Pao_2$  are not known.

The 2010 Guidelines defined an arterial oxygen saturation ( $Sao_2$ ) of less than 94% as hypoxemia, and there were no new data to suggest modifying this threshold. Minimizing risk of hyperoxia must be weighed against the need to avoid hypoxia, which has a well established detrimental effect.<sup>88,91,94</sup> Preventing hypoxic episodes is considered more important than avoiding any potential risk of hyperoxia.

**2015 Recommendations—New and Updated**—To avoid hypoxia in adults with ROSC after cardiac arrest, it is reasonable to use the highest available oxygen concentration until the arterial oxyhemoglobin saturation or the partial pressure of arterial oxygen can be measured (Class IIa, LOE C-EO).

When resources are available to titrate the  $F_{IO_2}$  and to monitor oxyhemoglobin saturation, it is reasonable to decrease the  $F_{IO_2}$  when oxyhemoglobin saturation is 100%, provided the oxyhemoglobin saturation can be maintained at 94% or greater (Class IIa, LOE C-LD).

Shortly after ROSC, patients may have peripheral vasoconstriction that makes measurement of oxyhemoglobin saturation by pulse oximetry difficult or unreliable. In those situations, arterial blood sampling may be required before titration of  $F_{IO_2}$ . Attempts to limit the concentration of inspired oxygen rely on having proper equipment available. For example, oxygen blenders may not be available immediately after return of pulses, and these recommendations remind providers using bag-mask devices and oxygen cylinders to simply provide the highest available oxygen concentration until titration is possible.

## Other Critical Care Interventions

### Glucose Control<sup>ALS 580</sup>

The 2010 Guidelines acknowledged that the optimum blood glucose concentration and interventional strategy to manage blood glucose in the post–cardiac arrest period are unknown. Glycemic control in critically ill patients is controversial, and efforts to tightly control glucose at low levels have been associated with increased frequency of hypoglycemic episodes that may be detrimental.

**2015 Evidence Summary—**The 2015 ILCOR systematic review found no new evidence that a specific target range for blood glucose management improved relevant clinical outcomes after cardiac arrest. One randomized trial in post–cardiac arrest patients comparing strict (72 to 108 mg/dL) versus moderate (108 to 144 mg/dL) glucose control found no difference in 30-day mortality.<sup>95</sup> One before-and-after study of a bundle of care that included a target glucose range (90 to 144 mg/dL) reported better survival and functional recovery at hospital discharge, but the effects of glucose control could not be separated from the remainder of the bundle.<sup>37</sup> No data suggest that the approach to glucose management chosen for other critically ill patients should be modified for cardiac arrest patients.<sup>96–98</sup>

**2015 Recommendation—Updated—**The benefit of any specific target range of glucose management is uncertain in adults with ROSC after cardiac arrest (Class IIb, LOE B-R).

## Prognostication of Outcome

The 2010 Guidelines discussed the use of clinical examination, electrophysiologic measurements, imaging studies, and evaluation of blood or cerebrospinal fluid markers of brain injury to estimate the prognosis for neurologic improvement in patients who are comatose after cardiac arrest. The 2015 ILCOR systematic review examined numerous studies of the diagnostic accuracy of clinical findings, electrophysiologic modalities, imaging modalities, and blood markers for predicting neurologic outcome in comatose post–cardiac arrest patients who receive TTM, and examined recent studies of these modalities in comatose post–cardiac arrest patients who do not receive TTM. Updated guidelines for prognostication have also been proposed by other international organizations.<sup>99</sup>

Most studies examined the accuracy of diagnostic tests for predicting a poor outcome (as defined by a Cerebral Performance Category score of 3 to 5) and focused on patients receiving TTM with a goal of 32°C to 34°C. The writing group assumed that the accuracy of prognostic tests is similar in patients receiving TTM with a goal of 36°C when similar sedation and paralysis are used as in patients receiving TTM with a goal of 32°C to 34°C. Recognizing the need for high certainty when predicting that outcomes will be poor, the writing group focused recommendations on diagnostic tests for which the systematic review identified false-positive rates (FPRs) close to 0%, with narrow 95% confidence intervals (CIs; 0%–10%).

Experienced clinicians should select the proper tests and studies for individual patients. Some patients will recover quickly and will require no special testing. For other patients, prediction of their recovery trajectory may be impossible despite collecting every available test and imaging study. The following recommendations are designed to provide guidance to clinicians about the performance of specific findings and tests, recognizing that not every patient will require every study.

### Timing of Outcome Prediction<sup>ALS 450, ALS 713</sup>

It is important to consider the optimal timing for prognostication in post–cardiac arrest patients. In 2015, the ILCOR task force evaluated the timing of prognostication for patients receiving TTM and for those not receiving TTM.

**2015 Evidence Summary**—Sedatives or neuromuscular blockers received during TTM may be metabolized more slowly in post–cardiac arrest patients, and injured brains may be more sensitive to the depressant effects of various medications. Residual sedation or paralysis can confound the accuracy of clinical examinations.<sup>100,101</sup> The optimal time for prognostication is when the FPRs of the various prognostic tools approach zero. Multiple investigations suggest that it is necessary to wait to prognosticate for a minimum of 72 hours after ROSC to minimize the rate of false-positive results in patients who had not undergone TTM<sup>102</sup> and to wait for some period of time after return of normothermia for those using TTM.<sup>103</sup>

**2015 Recommendations—New and Updated**—The earliest time for prognostication using clinical examination in patients treated with TTM, where sedation or paralysis could be a confounder, may be 72 hours after return to normothermia (Class IIb, LOE C-EO).

We recommend the earliest time to prognosticate a poor neurologic outcome using clinical examination in patients not treated with TTM is 72 hours after cardiac arrest (Class I, LOE B-NR). This time until prognostication can be even longer than 72 hours after cardiac arrest if the residual effect of sedation or paralysis confounds the clinical examination (Class IIa, LOE C-LD).

Operationally, the timing for prognostication is typically 4.5 to 5 days after ROSC for patients treated with TTM. This approach minimizes the possibility of obtaining false-positive results (ie, inaccurately suggesting a poor outcome) because of drug-induced depression of neurologic function. In making this recommendation, it is recognized that in some instances, withdrawal of life support may occur appropriately before 72 hours because of underlying terminal disease, brain herniation, or other clearly nonsurvivable situations.

### Clinical Examination Findings That Predict Outcome<sup>ALS 450, ALS 713</sup>

Prediction of outcome based on clinical examination may be challenging. In 2015, the ILCOR Advanced Life Support Task Force evaluated a series of clinical exam findings to determine their value in outcome prediction.

**2015 Evidence Summary**—The 2015 ILCOR systematic review examined pupillary light reflexes, corneal reflexes, and motor response for prediction of poor functional recovery in patients treated with TTM. Bilaterally absent pupillary light reflex at 72 to 108 hours after cardiac arrest predicted poor outcome, with an FPR of 1% (95% CI, 0%–3%).<sup>104–108</sup> Bilaterally absent corneal reflexes at 72 to 120 hours after cardiac arrest predicted poor outcome, with a 2% FPR (95% CI, 0%–7%).<sup>106–109</sup> Extensor posturing or no motor response to pain at 36 to 108 hours after cardiac arrest predicted poor outcome, with a 10% FPR (95% CI, 7%–15%).<sup>104,106,108,110–112</sup> Only the absent pupillary light reflex at 72 to 108 hours achieved an FPR of 0% (95% CI, 0%–3%).

In patients not treated with TTM, absent pupillary light reflex 72 hours after cardiac arrest predicts poor outcome, with 0% FPR (95% CI, 0%–8%).<sup>113,114</sup> Absent corneal reflex at 24 hours and 48 hours after cardiac arrest predicted poor outcome, with an FPR of 17% (95% CI, 9%–27%) and an FPR of 7% (95% CI, 2%–20%), respectively.<sup>114–116</sup> Extensor posturing or no motor response to pain at 72 hours after cardiac arrest predicted a poor outcome, with 15% FPR (95% CI, 5%–31%).<sup>114,117</sup> As in TTM-treated patients, only the absent pupillary light reflex at 72 to 108 hours achieved 0% FPR (95% CI, 0%–8%).

The 2015 ILCOR systematic review distinguished myoclonus from status myoclonus (continuous, repetitive myoclonic jerks lasting more than 30 minutes) in patients treated with TTM. Any myoclonus within 72 hours after cardiac arrest predicted a poor outcome, with a 5% FPR (95% CI, 3%–8%).<sup>78,104,110,111,118,119</sup> In 1 study,<sup>112</sup> presence of myoclonus within 7 days after ROSC predicted poor outcome, with 11% FPR (95% CI, 3%–26%) and 54% FPR (95% CI, 41%–66%) sensitivity. In 3 studies,<sup>75,107,108</sup> presence of status myoclonus (defined as a continuous prolonged and generalized myoclonus) within 72 to 120 hours after ROSC predicted poor outcome, with a 0% FPR (95% CI, 0%–4%). However, some series report good neurologic recovery in which an early-onset and prolonged myoclonus evolved into a chronic action myoclonus (Lance-Adams syndrome).<sup>118,121–123</sup> Therefore, the presence of any myoclonus is not a reliable predictor of poor functional recovery, but status myoclonus during the first 72 hours after cardiac arrest achieved an FPR of 0% (95% CI, 0%–4%).

In patients not treated with TTM, status myoclonus on admission (FPR, 0%; 95% CI, 0%–5%)<sup>124</sup> at 24 hours after cardiac arrest<sup>116</sup> (FPR, 0%; 95% CI, 0%–7%) or within 72 hours of cardiac arrest<sup>114,125</sup> (FPR, 0%; 95% CI, 0%–14%) is associated with poor outcome. The older studies were less precise in distinguishing myoclonus from status myoclonus, lowering confidence in their estimated predictive value.

**2015 Recommendations—New and Updated**—In comatose patients who are not treated with TTM, the absence of pupillary reflex to light at 72 hours or more after cardiac arrest is a reasonable exam finding with which to predict poor neurologic outcome (FPR, 0%; 95% CI, 0%–8%; Class IIa, LOE B-NR).

In comatose patients who are treated with TTM, the absence of pupillary reflex to light at 72 hours or more after cardiac arrest is useful to predict poor neurologic outcome (FPR, 1%; 95% CI, 0%–3%; Class I, LOE B-NR).

We recommend that, given their unacceptable FPRs, the findings of either absent motor movements or extensor posturing *should not* be used alone for predicting a poor neurologic outcome (FPR, 10%; 95% CI, 7%–15% to FPR, 15%; 95% CI, 5%–31%; Class III: Harm, LOE B-NR). The motor examination may be a reasonable means to identify the population who need further prognostic testing to predict poor outcome (Class IIb, LOE B-NR).

We recommend that the presence of myoclonus, which is distinct from status myoclonus, *should not* be used to predict poor neurologic outcomes because of the high FPR (FPR, 5%; 95% CI, 3%–8% to FPR, 11%; 95% CI, 3%–26%; Class III: Harm, LOE B-NR).

In combination with other diagnostic tests at 72 or more hours after cardiac arrest, the presence of status myoclonus during the first 72 to 120 hours after cardiac arrest is a reasonable finding to help predict poor neurologic outcomes (FPR, 0%; 95% CI, 0%–4%; Class IIa, LOE B-NR).

### EEG Findings to Predict Outcome<sup>ALS 450, ALS 713</sup>

EEG is a widely used tool to assess brain cortical activity and diagnose seizures. EEG is the standard tool used to assess brain electrical activity (ie, EEG rhythms) and paroxysmal activity (ie, seizures and bursts). While EEG has been used widely in the diagnosis of seizures and prognostication after cardiac arrest, the lack of standardized EEG terminology continues to be a major limitation in research and practice.<sup>126</sup>

**2015 Evidence Summary**—In patients treated with TTM, the 2015 ILCOR systematic review identified EEG with burst suppression, epileptiform activity, and reactivity as potential predictors of poor outcome. Two studies reported that burst suppression on initial EEG predicted poor outcome, with a 0% FPR (95% CI, 0%–5%),<sup>127,128</sup> but 2 other studies reported that EEG during TTM predicted poor outcome, with a 6% FPR (95% CI, 1%–15%).<sup>111,129</sup> Burst suppression after rewarming was associated with poor outcome<sup>128</sup> (FPR, 0%; 95% CI, 0%–5%). Some studies reported good outcome despite the presence of epileptiform discharges during TTM.<sup>110,130</sup> In several case series, no patients with electrographic seizures during or after TTM had good outcome,<sup>78,110,130–132</sup> but other studies reported cases with good outcome when seizures occurred in the presence of a reactive EEG background.<sup>118,128</sup> Absence of EEG reactivity during TTM predicted poor outcome, with an FPR of 2% (95% CI, 1%–7%),<sup>78,111,119</sup> and absence of EEG reactivity after rewarming predicted poor outcome, with an FPR of 0% (95% CI, 0%–3%).<sup>78,110,111</sup> Low-voltage EEG,<sup>128</sup> low bispectral index,<sup>133</sup> and EEG grades<sup>78</sup> were not reliably associated with poor outcome.

In patients not treated with TTM, the 2015 ILCOR systematic review identified EEG grades, burst suppression, and amplitude as potential predictors of poor outcome. EEG grades 4 to 5 at 72 hours or less after cardiac arrest predicted poor outcome, with a 0% FPR (95% CI, 0%–8%),<sup>134–136</sup> and burst suppression at 72 hours after cardiac arrest predicted poor outcome, with a 0% FPR (95% CI, 0%–11%).<sup>114</sup> EEG grades were not defined consistently between studies. Low-voltage EEG (< 20 to 21  $\mu$ V) predicted poor outcome, with 0% FPR (95% CI, 0%–5%) within 48 hours after cardiac arrest (1 study)<sup>116</sup> and with 0% FPR (95%

CI, 0%–11%) at 72 hours after cardiac arrest.<sup>114</sup> However, low-voltage EEG is not reliable, because a variety of technical factors can affect EEG amplitude.

**2015 Recommendations—Updated**—In comatose post–cardiac arrest patients who are treated with TTM, it may be reasonable to consider persistent absence of EEG reactivity to external stimuli at 72 hours after cardiac arrest, and persistent burst suppression on EEG after rewarming, to predict a poor outcome (FPR, 0%; 95% CI, 0%–3%; Class IIb, LOE B-NR).

Intractable and persistent (more than 72 hours) status epilepticus in the absence of EEG reactivity to external stimuli may be reasonable to predict poor outcome (Class IIb, LOE B-NR).

In comatose post–cardiac arrest patients who are not treated with TTM, it may be reasonable to consider the presence of burst suppression on EEG at 72 hours or more after cardiac arrest, in combination with other predictors, to predict a poor neurologic outcome (FPR, 0%; 95% CI, 0%–11%; Class IIb, LOE B-NR).

### Evoked Potentials to Predict Outcome<sup>ALS 450, ALS 713</sup>

The 2010 Guidelines advised that somatosensory evoked potentials (SSEPs) could be used as a prognostic tool in cardiac arrest survivors. The N20 waveform recorded from the primary cortical somatosensory area after median nerve stimulation was evaluated as a predictor of neurologic recovery in post–cardiac arrest patients.

**2015 Evidence Summary**—The 2015 systematic review found that in patients who are comatose after resuscitation from cardiac arrest and who are treated with TTM, bilaterally absent N20 was highly predictive of poor outcome. Absent N20 during TTM predicted poor outcome, with a 2% FPR (95% CI, 0%–4%).<sup>104,129,137,138</sup> Absent N20 after rewarming predicted poor outcome, with a 1% FPR (95% CI, 0%–3%).<sup>104–106,108,110–112,119,139,140</sup> One caution about these data is that SSEP has been used by healthcare providers and families as the parameter for withdrawal of life-sustaining therapies both in studies<sup>103</sup> and in bedside care, a practice that may inflate the apparent predictive accuracy of the test.

In patients not treated with TTM, bilateral absence of the N20 predicts poor outcome at 24, 48, or 72 hours after cardiac arrest (FPR, 0%; 95% CI, 0%–3% and 0%–12%).<sup>115,138,141–149</sup> Only 1 case of a false-positive result from absent SSEP in a patient not treated with TTM was identified.<sup>116</sup> Again, these studies may have allowed treating teams to act on the results of the SSEP, potentially inflating the accuracy of this test.

**2015 Recommendations—Updated**—In patients who are comatose after resuscitation from cardiac arrest regardless of treatment with TTM, it is reasonable to consider bilateral absence of the N20 SSEP wave 24 to 72 hours after cardiac arrest or after rewarming a predictor of poor outcome (FPR, 1%; 95% CI, 0%–3%; Class IIa, LOE B-NR).

SSEP recording requires appropriate skills and experience, and utmost care should be taken to avoid electrical interference from muscle artifacts or from the intensive care unit

environment. However, sedative drugs or temperature manipulation affect SSEPs less than they affect the EEG or clinical examination.<sup>138,150</sup>

### Imaging Tests to Predict Outcome<sup>ALS 450, ALS 713</sup>

Previous guidelines did not suggest specific imaging tests for prognosis in post-cardiac arrest coma. Brain imaging studies, including computed tomography (CT) or magnetic resonance imaging (MRI) can define structural brain injury or detect focal injury. On brain CT, some post-cardiac arrest patients exhibit brain edema, which can be quantified as the gray-white ratio (GWR), defined as the ratio between the x-ray attenuation measured in Hounsfield units of the gray matter and the white matter. Normal brain has GWR around 1.3, and this number decreases with edema.<sup>105</sup> Brain edema on MRI is a sensitive marker of focal injury and is detected by restricted diffusion on diffusion-weighted imaging (DWI) sequences<sup>151</sup> and can be quantified by using apparent diffusion coefficient (ADC). Normal ADC values range between 700 and 800 × 10<sup>-6</sup> mm<sup>2</sup>/s and decrease with edema.<sup>152</sup>

**2015 Evidence Summary**—The 2015 ILCOR systematic review identified 4 studies of CT scan performed within 2 hours after cardiac arrest in patients treated with TTM. A reduced GWR at the level of the basal ganglia on brain CT predicted poor outcome, with FPR ranging from 0% to 8%.<sup>105,153–155</sup> Measurement techniques and thresholds for GWR varied among studies. Global cerebral edema on brain CT at a median of 1 day after cardiac arrest also predicted poor outcome<sup>107</sup> (FPR, 0%; 95% CI, 0%–5%).

The 2015 ILCOR systematic review found 3 studies of CT scan on patients not treated with TTM. At 72 hours after cardiac arrest, the presence of diffuse brain swelling on CT predicted a poor outcome, with a 0% FPR (95% CI, 0%–45%).<sup>156</sup> In 2 studies, a GWR between the caudate nucleus and the posterior limb of internal capsule below 1.22 within 24 hours (FPR, 0%; 95% CI, 0%–28%) or below 1.18 within 48 hours (FPR, 17%; 95% CI, 0%–64%) after cardiac arrest predicted poor outcome.<sup>157,158</sup>

In patients treated with TTM, the 2015 systematic review identified two studies relating MRI findings to outcome. Presence of more than 10% of brain volume with ADC less than 650 × 10<sup>-6</sup> mm<sup>2</sup>/s predicted poor outcome<sup>159</sup> (FPR, 0%; 95% CI, 0%–78%). Low ADC at the level of putamen, thalamus, or occipital cortex predicted poor outcome, with 0% FPR<sup>160</sup> (95% CIs, from 0%–24%), although the ADC threshold in each region varied.

In patients not treated with TTM, 6 studies related MRI findings to poor outcome. Diffuse DWI abnormalities in cortex or brainstem at a median of 80 hours after cardiac arrest predicted poor outcome, with a 0% FPR (95% CI, 0%–35%).<sup>151</sup> Extensive (cortex, basal ganglia, and cerebellum) DWI changes predicted poor outcome, with a 0% FPR (95% CI, 0%–45%).<sup>161</sup> Whole-brain ADC less than 665 × 10<sup>-6</sup> mm<sup>2</sup>/s predicted poor outcome, with 0% FPR (95% CI, 0%–21%).<sup>162</sup> More than 10% of brain volume with ADC less than 650 × 10<sup>-6</sup> mm<sup>2</sup>/s predicted poor outcome, with 0% FPR (95% CI, 0%–28%).<sup>159</sup> ADC below various thresholds at the level of putamen, thalamus, or occipital cortex at less than 120 hours after cardiac arrest predicted poor outcome, with 0% FPR (95% CI, 0%–31%). The presence of extensive cortical global DWI or fluid-attenuated inversion recovery changes



within 7 days from arrest-predicted poor outcome, with a 0% FPR (95% CI, 0%–78%).<sup>117,152</sup>

MRI testing may be difficult in unstable patients, which may lead to selection bias. Studies report that DWI changes are most apparent more than 48 hours after cardiac arrest,<sup>159</sup> with most studies examining patients 3 to 7 days after cardiac arrest.

**2015 Recommendations—New**—In patients who are comatose after resuscitation from cardiac arrest and not treated with TTM, it may be reasonable to use the presence of a marked reduction of the GWR on brain CT obtained within 2 hours after cardiac arrest to predict poor outcome (Class IIb, LOE B-NR).

It may be reasonable to consider extensive restriction of diffusion on brain MRI at 2 to 6 days after cardiac arrest in combination with other established predictors to predict a poor neurologic outcome (Class IIb, LOE B-NR).

Acquisition and interpretation of imaging studies have not been fully standardized and are subject to interob-server variability.<sup>163</sup> In addition, the recommendations for brain imaging studies for prognostication are made with the assumption that images are performed in centers with expertise in this area.

### **Blood Markers to Predict Outcome** [ALS 450](#), [ALS 713](#)

Many blood markers have been examined for the prognostication of post-cardiac arrest patients. In 2015, the ILCOR Advanced Life Support Task Force evaluated whether blood markers can be used alone or in conjunction with other neurologic testing to prognosticate outcome in postarrest patients.

**2015 Evidence Summary**—The 2015 ILCOR systematic review examined many studies of blood markers to predict neurologic outcomes at various times after cardiac arrest, both in patients treated and not treated with TTM.<sup>104,106–108,111,114,119,132,133,145,147,155,160,164–176</sup> Neuron-specific enolase (NSE) and S-100B are the 2 most commonly examined blood markers.

Studies of NSE and S-100B reported that initial S-100B levels were higher in patients with poor outcome compared to patients with good outcome, and that NSE levels would increase over 72 hours in patients with poor outcome relative to patients with good outcome. However, studies did not identify specific blood levels of these proteins that enable prediction of poor neurologic outcome with perfect specificity and narrow confidence intervals. Therefore, no threshold values that enable prediction of poor outcome with confidence were identified.

**2015 Recommendations—Updated**—Given the possibility of high FPRs, blood levels of NSE and S-100B **should not** be used alone to predict a poor neurologic outcome (Class III: Harm, LOE C-LD).

When performed with other prognostic tests at 72 hours or more after cardiac arrest, it may be reasonable to consider high serum values of NSE at 48 to 72 hours after cardiac arrest to

support the prognosis of a poor neurologic outcome (Class IIb, LOE B-NR), especially if repeated sampling reveals persistently high values (Class IIb, LOE C-LD).

Laboratory standards for NSE and S-100B measurement vary between centers, making comparison of absolute values difficult. The kinetics of these markers have not been studied, particularly during or after TTM in cardiac arrest patients. Finally, NSE and S-100B are not specific to neuronal damage and can be produced by extra-central nervous system sources (hemolysis, neuroendocrine tumors, myenteric plexus, muscle, and adipose tissue breakdown). If care is not taken when drawing NSE levels and if multiple time points are not assessed, false-positive results could occur secondary to hemolysis. All of these limitations led the writing group to conclude that NSE should be limited to a confirmatory test rather than a primary method for estimating prognosis.

## Organ Donation<sup>ALS 449</sup>

The 2010 Guidelines emphasized that adult patients who progress to brain death after resuscitation from cardiac arrest should be considered as potential organ donors.

### 2015 Evidence Summary

The 2015 ILCOR systematic reviews considered the success rate of transplants when organs are taken from adult and pediatric donors who progressed to death or brain death after cardiac arrest. Post-cardiac arrest patients are an increasing proportion of the pool of organ donors.<sup>177</sup> When patients who have previously had cardiopulmonary resuscitation proceed to become organ donors, each donor provides a mean of 3.9<sup>178</sup> or 2.9<sup>177</sup> organs. Multiple studies found no difference in immediate or long-term function of organs from donors who reach brain death after cardiac arrest when compared with donors who reach brain death from other causes. In addition, some patients have withdrawal of life support after cardiac arrest as a consequence of failure to improve neurologically or as part of advanced directives, which can lead to cardiovascular death in a predictable time frame that may allow donation of kidney or liver. Organs transplanted from these donors also have success rates comparable to similar donors with other conditions. These studies examined adult hearts,<sup>177,179–185</sup> pediatric hearts,<sup>177,186–189</sup> adult lungs,<sup>177,183,190</sup> pediatric lungs,<sup>177</sup> adult kidneys,<sup>177,191</sup> pediatric kidneys,<sup>177,188</sup> adult livers,<sup>177,179</sup> pediatric livers,<sup>177,188</sup> adult intestines,<sup>177,192</sup> and pediatric intestines.<sup>177</sup> Finally, tissue donation (cornea, skin, and bone) is almost always possible if post-cardiac arrest patients die.

A few programs have developed procedures for recovery of kidney and liver when return of pulses cannot be achieved. Existing programs rely on continued mechanical circulatory support and very rapid mobilization of surgeons and transplant teams after a patient is unexpectedly pronounced dead. The resources to accomplish these donations require significant institutional preparation. These programs also require careful and thoughtful safeguards to prevent donation efforts from interfering with ongoing resuscitation efforts. A mean of 1.5<sup>193</sup> or 3.2<sup>194</sup> organs were procured from each donor in these programs. Function of adult kidneys<sup>195–197</sup> or adult livers<sup>193,196,198</sup> from these donors was similar immediately, 1 year, and 5 years after transplantation.

## 2015 Recommendations—Updated and New

We recommend that all patients who are resuscitated from cardiac arrest but who subsequently progress to death or brain death be evaluated for organ donation (Class I, LOE B-NR).

Patients who do not have ROSC after resuscitation efforts and who would otherwise have termination of efforts may be considered candidates for kidney or liver donation in settings where programs exist (Class IIb, LOE B-NR). The ethics and practical aspects of these programs are quite complex and beyond the scope of this review.

## Conclusions and Future Directions

The field of post–cardiac arrest care has increased in rigor and depth over the past decade. Investigations over this period illustrate the heterogeneity of patients hospitalized after cardiac arrest in terms of etiology, comorbid disease, and illness severity. Future interventional trials should ideally be designed to take into account patient heterogeneity and focus interventions on the specific subgroups most likely to benefit. By tailoring interventions to patient physiology and disease, a greater chance exists that the right therapies will be matched to the patients who will benefit.

## Appendix

### 2015 Guidelines Update: Part 8 Recommendations

Year Last Reviewed	Topic	Recommendation	Comments
2015	Cardiovascular Care	Coronary angiography should be performed emergently (rather than later in the hospital stay or not at all) for OHCA patients with suspected cardiac etiology of arrest and ST elevation on ECG (Class I, LOE B-NR).	updated for 2015
2015	Cardiovascular Care	Emergent coronary angiography is reasonable for select (e.g. electrically or hemodynamically unstable) adult patients who are comatose after OHCA of suspected cardiac origin but without ST elevation on ECG (Class IIa, LOE B-NR).	updated for 2015
2015	Cardiovascular Care	Coronary angiography is reasonable in post–cardiac arrest patients for whom coronary angiography is indicated regardless of whether the patient is comatose or awake (Class IIa, LOE C-LD).	updated for 2015
2015	Hemodynamic Goals	Avoiding and immediately correcting hypotension (systolic blood pressure less than 90 mm Hg, MAP less than 65 mm Hg) during postresuscitation care may be reasonable (Class IIb, LOE C-LD).	new for 2015
2015	Targeted Temperature Management	We recommend that comatose (ie, lack of meaningful response to verbal commands) adult patients with ROSC after cardiac arrest have TTM (Class I, LOE B-R for VF/pVT OHCA; Class I, LOE C-EO for non-VF/pVT (ie, “nonshockable”) and in-hospital cardiac arrest).	updated for 2015
2015	Targeted Temperature Management	We recommend selecting and maintaining a constant temperature between 32°C and 36°C during TTM (Class I, LOE B-R).	updated for 2015
2015	Targeted Temperature Management	It is reasonable that TTM be maintained for at least 24 hours after achieving target temperature (Class IIa,	updated for 2015

Year Last Reviewed	Topic	Recommendation	Comments
		LOE C-EO).	
2015	Targeted Temperature Management	We recommend against the routine prehospital cooling of patients after ROSC with rapid infusion of cold intravenous fluids (Class III: No Benefit, LOE A).	new for 2015
2015	Targeted Temperature Management	It may be reasonable to actively prevent fever in comatose patients after TTM (Class IIb, LOE C-LD).	new for 2015
2015	Other Neurologic Care	An EEG for the diagnosis of seizure should be promptly performed and interpreted, and then should be monitored frequently or continuously in comatose patients after ROSC (Class I, LOE C-LD).	updated for 2015
2015	Other Neurologic Care	The same anticonvulsant regimens for the treatment of status epilepticus caused by other etiologies may be considered after cardiac arrest (Class IIb, LOE C-LD).	updated for 2015
2015	Respiratory Care	Maintaining the PaCO <sub>2</sub> within a normal physiological range, taking into account any temperature correction, may be reasonable (Class IIb, LOE B-NR).	updated for 2015
2015	Respiratory Care	To avoid hypoxia in adults with ROSC after cardiac arrest, it is reasonable to use the highest available oxygen concentration until the arterial oxyhemoglobin saturation or the partial pressure of arterial oxygen can be measured (Class IIa, LOE C-EO).	new for 2015
2015	Respiratory Care	When resources are available to titrate the FIO <sub>2</sub> and to monitor oxyhemoglobin saturation, it is reasonable to decrease the FIO <sub>2</sub> when oxyhemoglobin saturation is 100%, provided the oxyhemoglobin saturation can be maintained at 94% or greater (Class IIa, LOE C-LD).	updated for 2015
2015	Other Critical Care Interventions	The benefit of any specific target range of glucose management is uncertain in adults with ROSC after cardiac arrest (Class IIb, LOE B-R).	updated for 2015
2015	Prognostication of Outcome	The earliest time for prognostication using clinical examination in patients treated with TTM, where sedation or paralysis could be a confounder, may be 72 hours after normothermia (Class IIb, LOE C-EO).	updated for 2015
2015	Other Critical Care Interventions	We recommend the earliest time to prognosticate a poor neurologic outcome using clinical examination in patients not treated with TTM is 72 hours after cardiac arrest (Class I, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	This time until prognostication can be even longer than 72 hours after cardiac arrest if the residual effect of sedation or paralysis confounds the clinical examination (Class IIa, LOE C-LD).	new for 2015
2015	Other Critical Care Interventions	In comatose patients who are not treated with TTM, the absence of pupillary reflex to light at 72 hours or more after cardiac arrest is a reasonable exam finding with which to predict poor neurologic outcome (FPR, 0%; 95% CI, 0%–8%; Class IIa, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	In comatose patients who are treated with TTM, the absence of pupillary reflex to light at 72 hours or more after cardiac arrest is useful to predict poor neurologic outcome (FPR, 1%; 95% CI, 0%–3%; Class I, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	We recommend that, given their unacceptable FPRs, the findings of either absent motor movements or extensor posturing should not be used alone for predicting a poor neurologic outcome (FPR, 10%; 95% CI, 7%–15% to FPR, 15%; 95% CI, 5%–31%; Class III: Harm, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	The motor examination may be a reasonable means to identify the population who need further prognostic	new for 2015

Year Last Reviewed	Topic	Recommendation	Comments
		testing to predict poor outcome (Class IIb, LOE B-NR).	
2015	Other Critical Care Interventions	We recommend that the presence of myoclonus, which is distinct from status myoclonus, should not be used to predict poor neurologic outcomes because of the high FPR (FPR, 5%; 95% CI, 3%–8% to FPR, 11%; 95% CI, 3%–26%; Class III: Harm, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	In combination with other diagnostic tests at 72 or more hours after cardiac arrest, the presence of status myoclonus during the first 72 to 120 hours after cardiac arrest is a reasonable finding to help predict poor neurologic outcomes (FPR, 0%; 95% CI, 0%–4%; Class IIa, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	In comatose post–cardiac arrest patients who are treated with TTM, it may be reasonable to consider persistent absence of EEG reactivity to external stimuli at 72 hours after cardiac arrest, and persistent burst suppression on EEG after rewarming, to predict a poor outcome (FPR, 0%; 95% CI, 0%–3%; Class IIb, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	Intractable and persistent (more than 72 hours) status epilepticus in the absence of EEG reactivity to external stimuli may be reasonable to predict poor outcome (Class IIb, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	In comatose post–cardiac arrest patients who are not treated with TTM, it may be reasonable to consider the presence of burst suppression on EEG at 72 hours or more after cardiac arrest, in combination with other predictors, to predict a poor neurologic outcome (FPR, 0%; 95% CI, 0%–11%; Class IIb, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	In patients who are comatose after resuscitation from cardiac arrest regardless of treatment with TTM, it is reasonable to consider bilateral absence of the N20 SSEP wave 24 to 72 hours after cardiac arrest or after rewarming a predictor of poor outcome (FPR, 1%; 95% CI, 0%–3%; Class IIa, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	In patients who are comatose after resuscitation from cardiac arrest and not treated with TTM, it may be reasonable to use the presence of a marked reduction of the GWR on brain CT obtained within 2 hours after cardiac arrest to predict poor outcome (Class IIb, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	It may be reasonable to consider extensive restriction of diffusion on brain MRI at 2 to 6 days after cardiac arrest in combination with other established predictors to predict a poor neurologic outcome (Class IIb, LOE B-NR).	new for 2015
2015	Other Critical Care Interventions	Given the possibility of high FPRs, blood levels of NSE and S-100B should not be used alone to predict a poor neurologic outcome (Class III: Harm, LOE C-LD).	updated for 2015
2015	Other Critical Care Interventions	When performed with other prognostic tests at 72 hours or more after cardiac arrest, it may be reasonable to consider high serum values of NSE at 48 to 72 hours after cardiac arrest to support the prognosis of a poor neurologic outcome (Class IIb, LOE B-NR), especially if repeated sampling reveals persistently high values (Class IIb, LOE C-LD).	updated for 2015
2015	Other Critical Care Interventions	We recommend that all patients who are resuscitated from cardiac arrest but who subsequently progress to death or brain death be evaluated for organ donation (Class I, LOE B-NR).	updated for 2015
2015	Other Critical Care Interventions	Patients who do not have ROSC after resuscitation efforts and who would otherwise have termination of efforts may be considered candidates for kidney or liver donation in settings where programs exist (Class	new for 2015

Year Last Reviewed	Topic	Recommendation	Comments
		Iib, LOE B-NR).	
The following recommendations were not reviewed in 2015. For more information, see the <i>2010 AHA Guidelines for CPR and ECC</i> , "Part 9: Post-Cardiac Arrest Care."			
2010	Systems of Care for Improving Post-Cardiac Arrest Outcomes	A comprehensive, structured, multidisciplinary system of care should be implemented in a consistent manner for the treatment of post-cardiac arrest patients (Class I, LOE B).	not reviewed in 2015
2010	Treatment of Pulmonary Embolism After CPR	In post-cardiac arrest patients with arrest due to presumed or known pulmonary embolism, fibrinolytics may be considered (Class Iib, LOE C).	not reviewed in 2015
2010	Sedation After Cardiac Arrest	It is reasonable to consider the titrated use of sedation and analgesia in critically ill patients who require mechanical ventilation or shivering suppression during induced hypothermia after cardiac arrest (Class Iib, LOE C).	not reviewed in 2015
2010	Cardiovascular System	A 12-lead ECG should be obtained as soon as possible after ROSC to determine whether acute ST elevation is present (Class I, LOE B).	not reviewed in 2015
2010	Neuroprotective	The routine use of coenzyme Q10 in patients treated with hypothermia is uncertain (Class Iib, LOE B).	not reviewed in 2015
2010	Evoked Potentials	Bilateral absence of the N20 cortical response to median nerve stimulation after 24 hours predicts poor outcome in comatose cardiac arrest survivors not treated with therapeutic hypothermia (Class Iia, LOE A).	not reviewed in 2015

### Disclosures

Part 8: Post-Cardiac Arrest Care: 2015 Guidelines Update Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Clifton W. Callaway	University of Pittsburgh; UPMC Health System	None	None	None	None	None	None	None
Ericka L. Fink	Children's Hospital of Pittsburgh of UPMC	NIH <sup>†</sup> ; Laerdal Foundation <sup>‡</sup>	None	None	None	None	None	None
Romergrzyko G. Geocadin	Johns Hopkins University School of Medicine	NIH <sup>†</sup>	None	None	Medicolegal consulting*	None	None	None
Eyal Golan	University Health Network	None	None	None	None	None	None	None
Karl B. Kern	University of Arizona	Zoll Medical <sup>‡</sup> ; PhysioControl <sup>‡</sup> ; Arizona Biomedical Research Association <sup>‡</sup>	None	BARD, Inc.	None	None	None	None
Marion Leary	University of Pennsylvania	American Heart Association <sup>‡</sup> ; Laerdal <sup>‡</sup>	None	None	None	Resuscor*	PhysioControl <sup>‡</sup> ; Laerdal	None
William J. Meurer	University of Michigan	None	None	None	None	None	None	None
Mary Ann Peberdy	Virginia Commonwealth University	Zoll Medical <sup>‡</sup>	None	None	None	None	None	None
Trevonne M. Thompson	University of Illinois at Chicago	None	None	None	None	None	None	None
Janice L. Zimmerman	The Methodist Hospital Physician Organization	None	None	None	None	None	Decisio Health, Inc	None
<b>Consultant</b>								
Michael W. Donnino	Beth Israel Deaconess Med Center	American Heart Association <sup>‡</sup>	None	None	None	None	American Heart Association <sup>‡</sup>	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\* Modest.

<sup>‡</sup> Significant.

## References

1. Morrison LJ, Deakin CD, Morley PT, Callaway CW, Kerber RE, Kronick SL, Lavonas EJ, Link MS, Neumar RW, Otto CW, Parr M, Shuster M, Sunde K, Peberdy MA, Tang W, Hoek TL, Böttiger BW, Drajer S, Lim SH, Nolan JP. Advanced Life Support Chapter Collaborators. Part 8: advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2010; 122(suppl 2):S345–S421. [PubMed: 20956256]
2. Deakin CD, Morrison LJ, Morley PT, Callaway CW, Kerber RE, Kronick SL, Lavonas EJ, Link MS, Neumar RW, Otto CW, Parr M, Shuster M, Sunde K, Peberdy MA, Tang W, Hoek TL, Böttiger BW, Drajer S, Lim SH, Nolan JP. Advanced Life Support Chapter Collaborators. Part 8: advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Resuscitation*. 2010; 81(suppl 1):e93–e174. [PubMed: 20956032]
3. Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O’Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J. on behalf of the Advanced Life Support Chapter Collaborators. Part 4: advanced life support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015; 132(suppl 1):S84–S145. [PubMed: 26472860]
4. Soar J, Callaway CW, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O’Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J. on behalf of the Advanced Life Support Chapter Collaborators. Part 4: advanced life support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Resuscitation*. 2015 In press.
5. Chapter 5: defining the review questions and developing criteria for including studies. In: O’Connor, D.; Green, S., editors; *The Cochrane Collaboration*. Higgins, JPT.; Green, S., editors. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0. 2011. <http://handbook.cochrane.org/> [Accessed May 6, 2015]
6. Schünemann, H.; Bro ek, J.; Guyatt, G.; Oxman, A. *GRADE Handbook*. 2013. <http://www.guidelinedevelopment.org/handbook/> [Accessed May 6, 2015]
7. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, Clark RS, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT Jr, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Vanden Hoek T. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. *Circulation*. 2008; 118:2452–2483. [PubMed: 18948368]
8. Davies MJ. Anatomic features in victims of sudden coronary death. *Coronary artery pathology*. *Circulation*. 1992; 85(1 suppl):I19–I24. [PubMed: 1728500]
9. Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut JF, Carli P. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. *N Engl J Med*. 1997; 336:1629–1633. [PubMed: 9171064]
10. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, Empana JP, Carli P, Mira JP, Jouven X, Spaulding C. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac Arrest) registry. *Circ Cardiovasc Interv*. 2010; 3:200–207. [PubMed: 20484098]



11. Hollenbeck RD, McPherson JA, Mooney MR, Unger BT, Patel NC, McMullan PW Jr, Hsu CH, Seder DB, Kern KB. Early cardiac catheterization is associated with improved survival in comatose survivors of cardiac arrest without STEMI. *Resuscitation*. 2014; 85:88–95. [PubMed: 23927955]
12. Mooney MR, Unger BT, Boland LL, Burke MN, Kebed KY, Graham KJ, Henry TD, Katsiyannis WT, Satterlee PA, Sendelbach S, Hodges JS, Parham WM. Therapeutic hypothermia after out-of-hospital cardiac arrest: evaluation of a regional system to increase access to cooling. *Circulation*. 2011; 124:206–214. [PubMed: 21747066]
13. Gräsner JT, Meybohm P, Lefering R, Wnent J, Bahr J, Messelken M, Jantzen T, Franz R, Scholz J, Schleggers A, Böttiger BW, Bein B, Fischer M. German Resuscitation Registry Study Group. ROSC after cardiac arrest—the RACA score to predict outcome after out-of-hospital cardiac arrest. *Eur Heart J*. 2011; 32:1649–1656. [PubMed: 21515626]
14. Cronier P, Vignon P, Bouferrache K, Aegerter P, Charron C, Templier F, Castro S, El Mahmoud R, Lory C, Pichon N, Dubourg O, Vieillard-Baron A. Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. *Crit Care*. 2011; 15:R122. [PubMed: 21569361]
15. Bulut S, Aengevaeren WR, Luijten HJ, Verheugt FW. Successful out-of-hospital cardiopulmonary resuscitation: what is the optimal in-hospital treatment strategy? *Resuscitation*. 2000; 47:155–161. [PubMed: 11008153]
16. Bro-Jeppesen J, Kjaergaard J, Wanscher M, Pedersen F, Holmvang L, Lippert FK, Møller JE, Køber L, Hassager C. Emergency coronary angiography in comatose cardiac arrest patients: do real-life experiences support the guidelines? *Eur Heart J Acute Cardiovasc Care*. 2012; 1:291–301. [PubMed: 24062920]
17. Aurore A, Jabre P, Liot P, Margenet A, Lecarpentier E, Combes X. Predictive factors for positive coronary angiography in out-of-hospital cardiac arrest patients. *Eur J Emerg Med*. 2011; 18:73–76. [PubMed: 20664351]
18. Nanjaya VB, Nayyar V. Immediate coronary angiogram in comatose survivors of out-of-hospital cardiac arrest—an Australian study. *Resuscitation*. 2012; 83:699–704. [PubMed: 22178796]
19. Reynolds JC, Callaway CW, El Khoudary SR, Moore CG, Alvarez RJ, Rittenberger JC. Coronary angiography predicts improved outcome following cardiac arrest: propensity-adjusted analysis. *J Intensive Care Med*. 2009; 24:179–186. [PubMed: 19321536]
20. Strote JA, Maynard C, Olsufka M, Nichol G, Copass MK, Cobb LA, Kim F. Comparison of role of early (less than six hours) to later (more than six hours) or no cardiac catheterization after resuscitation from out-of-hospital cardiac arrest. *Am J Cardiol*. 2012; 109:451–454. [PubMed: 22100026]
21. Tømte O, Andersen GØ, Jacobsen D, Drægni T, Auestad B, Sunde K. Strong and weak aspects of an established post-resuscitation treatment protocol—A five-year observational study. *Resuscitation*. 2011; 82:1186–1193. [PubMed: 21636202]
22. Waldo SW, Armstrong EJ, Kulkarni A, Hoffmayer K, Kinlay S, Hsue P, Ganz P, McCabe JM. Comparison of clinical characteristics and outcomes of cardiac arrest survivors having versus not having coronary angiography. *Am J Cardiol*. 2013; 111:1253–1258. [PubMed: 23391104]
23. Nielsen N, Hovdenes J, Nilsson F, Rubertsson S, Stammet P, Sunde K, Valsson F, Wanscher M, Friberg H. Hypothermia Network. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. *Acta Anaesthesiol Scand*. 2009; 53:926–934. [PubMed: 19549271]
24. Werling M, Thorén AB, Axelsson C, Herlitz J. Treatment and outcome in post-resuscitation care after out-of-hospital cardiac arrest when a modern therapeutic approach was introduced. *Resuscitation*. 2007; 73:40–45. [PubMed: 17241730]
25. Zanuttini D, Armellini I, Nucifora G, Carchietti E, Trillò G, Spedicato L, Bernardi G, Proclemer A. Impact of emergency coronary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest. *Am J Cardiol*. 2012; 110:1723–1728. [PubMed: 22975468]
26. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:

- executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013; 127:529–555. [PubMed: 23247303]
27. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2012; 126:875–910. [PubMed: 22800849]
  28. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012; 33:2569–2619. [PubMed: 22922416]
  29. Peberdy MA, Donnino MW, Callaway CW, Dimaio JM, Geocadin RG, Ghaemmaghami CA, Jacobs AK, Kern KB, Levy JH, Link MS, Menon V, Ornato JP, Pinto DS, Sugarman J, Yannopoulos D, Ferguson TB Jr. on behalf of the American Heart Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Impact of percutaneous coronary intervention performance reporting on cardiac resuscitation centers: a scientific statement from the American Heart Association. *Circulation*. 2013; 128:762–773. [PubMed: 23857321]
  30. Trzeciak S, Jones AE, Kilgannon JH, Milcarek B, Hunter K, Shapiro NI, Hollenberg SM, Dellinger P, Parrillo JE. Significance of arterial hypotension after resuscitation from cardiac arrest. *Crit Care Med*. 2009; 37:2895–903. quiz 2904. [PubMed: 19866506]
  31. Bray JE, Bernard S, Cantwell K, Stephenson M, Smith K. VACAR Steering Committee. The association between systolic blood pressure on arrival at hospital and outcome in adults surviving from out-of-hospital cardiac arrests of presumed cardiac aetiology. *Resuscitation*. 2014; 85:509–515. [PubMed: 24333351]
  32. Kilgannon JH, Roberts BW, Reihl LR, Chansky ME, Jones AE, Dellinger RP, Parrillo JE, Trzeciak S. Early arterial hypotension is common in the post-cardiac arrest syndrome and associated with increased in-hospital mortality. *Resuscitation*. 2008; 79:410–416. [PubMed: 18990478]
  33. Müllner M, Sterz F, Binder M, Hellwagner K, Meron G, Herkner H, Laggner AN. Arterial blood pressure after human cardiac arrest and neurological recovery. *Stroke*. 1996; 27:59–62. [PubMed: 8553404]
  34. Beylin ME, Perman SM, Abella BS, Leary M, Shofer FS, Grossestreuer AV, Gaieski DF. Higher mean arterial pressure with or without vasoactive agents is associated with increased survival and better neurological outcomes in comatose survivors of cardiac arrest. *Intensive Care Med*. 2013; 39:1981–1988. [PubMed: 23995983]
  35. Gaieski DF, Band RA, Abella BS, Neumar RW, Fuchs BD, Kolansky DM, Merchant RM, Carr BG, Becker LB, Maguire C, Klair A, Hylton J, Goyal M. Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest. *Resuscitation*. 2009; 80:418–424. [PubMed: 19217200]
  36. Laurent I, Monchi M, Chiche JD, Joly LM, Spaulding C, Bourgeois B, Cariou A, Rozenberg A, Carli P, Weber S, Dhainaut JF. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. *J Am Coll Cardiol*. 2002; 40:2110–2116. [PubMed: 12505221]
  37. Sunde K, Pytte M, Jacobsen D, Mangschau A, Jensen LP, Smedsrud C, Draegni T, Steen PA. Implementation of a standardised treatment protocol for post resuscitation care after out-of-hospital cardiac arrest. *Resuscitation*. 2007; 73:29–39. [PubMed: 17258378]
  38. Walters EL, Morawski K, Dorotta I, Ramsingh D, Lumen K, Bland D, Clem K, Nguyen HB. Implementation of a post-cardiac arrest care bundle including therapeutic hypothermia and hemodynamic optimization in comatose patients with return of spontaneous circulation after out-of-hospital cardiac arrest: a feasibility study. *Shock*. 2011; 35:360–366. [PubMed: 21068697]

39. Donnino M, Andersen LW, Berg KM, et al. Temperature management after cardiac arrest: an advisory statement by the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR). *Circulation*. In press.
40. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med*. 2002; 346:549–556. [PubMed: 11856793]
41. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med*. 2002; 346:557–563. [PubMed: 11856794]
42. Dumas F, Grimaldi D, Zuber B, Fichet J, Charpentier J, Pène F, Vivien B, Varenne O, Carli P, Jouven X, Empana JP, Cariou A. Is hypothermia after cardiac arrest effective in both shockable and nonshockable patients?: insights from a large registry. *Circulation*. 2011; 123:877–886. [PubMed: 21321156]
43. Testori C, Sterz F, Behringer W, Haugk M, Uray T, Zeiner A, Janata A, Arrich J, Holzer M, Losert H. Mild therapeutic hypothermia is associated with favourable outcome in patients after cardiac arrest with non-shockable rhythms. *Resuscitation*. 2011; 82:1162–1167. [PubMed: 21705132]
44. Vaahersalo J, Hiltunen P, Tiainen M, Oksanen T, Kaukonen KM, Kurola J, Ruokonen E, Tenhunen J, Ala-Kokko T, Lund V, Reinikainen M, Kiviniemi O, Silfvast T, Kuisma M, Varpula T, Pettilä V. FINNRESUSCI Study Group. Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive care units: the FINNRESUSCI study. *Intensive Care Med*. 2013; 39:826–837. [PubMed: 23417209]
45. Mader TJ, Nathanson BH, Soares WE 3rd, Coute RA, McNally BF. Comparative Effectiveness of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: Insight from a Large Data Registry. *Ther Hypothermia Temp Manag*. 2014; 4:21–31. [PubMed: 24660100]
46. Nichol G, Huszti E, Kim F, Fly D, Parnia S, Donnino M, Sorenson T, Callaway CW. American Heart Association Get With The Guideline-Resuscitation Investigators. Does induction of hypothermia improve outcomes after in-hospital cardiac arrest? *Resuscitation*. 2013; 84:620–625. [PubMed: 23246514]
47. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammed P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H. TTM Trial Investigators. Targeted temperature management at 33°C versus 36°C after cardiac arrest. *N Engl J Med*. 2013; 369:2197–2206. [PubMed: 24237006]
48. Watts DD, Trask A, Soeken K, Perdue P, Dols S, Kaufmann C. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. *J Trauma*. 1998; 44:846–854. [PubMed: 9603087]
49. Lavinio A, Scudellari A, Gupta AK. Hemorrhagic shock resulting in cardiac arrest: is therapeutic hypothermia contraindicated? *Minerva Anesthesiol*. 2012; 78:969–970. [PubMed: 22415438]
50. Williams K, Rosen M, Buttram S, Zempel J, Pineda J, Miller B, Shoykhet M. Hypothermia for pediatric refractory status epilepticus. *Epilepsia*. 2013; 54:1586–1594. [PubMed: 23906244]
51. Corry JJ, Dhar R, Murphy T, Diringner MN. Hypothermia for refractory status epilepticus. *Neurocrit Care*. 2008; 9:189–197. [PubMed: 18415032]
52. Guluma KZ, Oh H, Yu SW, Meyer BC, Rapp K, Lyden PD. Effect of endovascular hypothermia on acute ischemic edema: morphometric analysis of the ICTuS trial. *Neurocrit Care*. 2008; 8:42–47. [PubMed: 17922082]
53. Kim F, Olsufka M, Longstreth WT Jr, Maynard C, Carlbom D, Deem S, Kudenchuk P, Copass MK, Cobb LA. Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4 degrees C normal saline. *Circulation*. 2007; 115:3064–3070. [PubMed: 17548731]
54. Kämäräinen A, Virkkunen I, Tenhunen J, Yli-Hankala A, Silfvast T. Prehospital therapeutic hypothermia for comatose survivors of cardiac arrest: a randomized controlled trial. *Acta Anaesthesiol Scand*. 2009; 53:900–907. [PubMed: 19496762]
55. Bernard SA, Smith K, Cameron P, Masci K, Taylor DM, Cooper DJ, Kelly AM, Silvester W. Rapid Infusion of Cold Hartmanns (RICH) Investigators. Induction of therapeutic hypothermia by

- paramedics after resuscitation from out-of-hospital ventricular fibrillation cardiac arrest: a randomized controlled trial. *Circulation*. 2010; 122:737–742. [PubMed: 20679551]
56. Bernard SA, Smith K, Cameron P, Masci K, Taylor DM, Cooper DJ, Kelly AM, Silvester W. Rapid Infusion of Cold Hartmanns Investigators. Induction of prehospital therapeutic hypothermia after resuscitation from nonventricular fibrillation cardiac arrest. *Crit Care Med*. 2012; 40:747–753. [PubMed: 22020244]
  57. Kim F, Nichol G, Maynard C, Hallstrom A, Kudenchuk PJ, Rea T, Copass MK, Carlbom D, Deem S, Longstreth WT Jr, Olsufka M, Cobb LA. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. *JAMA*. 2014; 311:45–52. [PubMed: 24240712]
  58. Debaty G, Maignan M, Savary D, Koch FX, Ruckly S, Durand M, Picard J, Escallier C, Chouquer R, Santre C, Minet C, Guergour D, Hammer L, Bouvaist H, Belle L, Adrie C, Payen JF, Carpentier F, Gueugniaud PY, Danel V, Timsit JF. Impact of intra-arrest therapeutic hypothermia in outcomes of prehospital cardiac arrest: a randomized controlled trial. *Intensive Care Med*. 2014; 40:1832–1842. [PubMed: 25348858]
  59. Castrén M, Nordberg P, Svensson L, Taccone F, Vincent JL, Desruelles D, Eichwede F, Mols P, Schwab T, Vergnion M, Storm C, Pesenti A, Pacht J, Guérisse F, Elste T, Roessler M, Fritz H, Durnez P, Busch HJ, Inderbitzen B, Barbut D. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). *Circulation*. 2010; 122:729–736. [PubMed: 20679548]
  60. Zeiner A, Holzer M, Sterz F, Schörkhuber W, Eisenburger P, Havel C, Kliegel A, Laggner AN. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. *Arch Intern Med*. 2001; 161:2007–2012. [PubMed: 11525703]
  61. Langhelle A, Tyvold SS, Lexow K, Hapnes SA, Sunde K, Steen PA. In-hospital factors associated with improved outcome after out-of-hospital cardiac arrest. A comparison between four regions in Norway. *Resuscitation*. 2003; 56:247–263. [PubMed: 12628556]
  62. Nolan JP, Laver SR, Welch CA, Harrison DA, Gupta V, Rowan K. Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database. *Anaesthesia*. 2007; 62:1207–1216. [PubMed: 17991255]
  63. Suffoletto B, Peberdy MA, van der Hoek T, Callaway C. Body temperature changes are associated with outcomes following in-hospital cardiac arrest and return of spontaneous circulation. *Resuscitation*. 2009; 80:1365–1370. [PubMed: 19804929]
  64. Gebhardt K, Guyette FX, Doshi AA, Callaway CW, Rittenberger JC. Post Cardiac Arrest Service. Prevalence and effect of fever on outcome following resuscitation from cardiac arrest. *Resuscitation*. 2013; 84:1062–1067. [PubMed: 23619740]
  65. Aldhoon B, Melenovsky V, Kettner J, Kautzner J. Clinical predictors of outcome in survivors of out-of-hospital cardiac arrest treated with hypothermia. *Cor et Vasa*. 2012; 54:e68–e75.
  66. Benz-Woerner J, Delodder F, Benz R, Cueni-Villoz N, Feihl F, Rossetti AO, Liaudet L, Oddo M. Body temperature regulation and outcome after cardiac arrest and therapeutic hypothermia. *Resuscitation*. 2012; 83:338–342. [PubMed: 22079947]
  67. Bouwes A, Robillard LB, Binnekade JM, de Pont AC, Wieske L, Hartog AW, Schultz MJ, Horn J. The influence of rewarming after therapeutic hypothermia on outcome after cardiac arrest. *Resuscitation*. 2012; 83:996–1000. [PubMed: 22521448]
  68. Leary M, Grossestreuer AV, Iannacone S, Gonzalez M, Shofer FS, Povey C, Wendell G, Archer SE, Gaieski DF, Abella BS. Pyrexia and neurologic outcomes after therapeutic hypothermia for cardiac arrest. *Resuscitation*. 2013; 84:1056–1061. [PubMed: 23153649]
  69. Cocchi MN, Boone MD, Giberson B, Giberson T, Farrell E, Saliccioli JD, Talmor D, Williams D, Donnino MW. Fever after rewarming: incidence of pyrexia in postcardiac arrest patients who have undergone mild therapeutic hypothermia. *J Intensive Care Med*. 2014; 29:365–369. [PubMed: 23783999]
  70. Bro-Jeppesen J, Hassager C, Wanscher M, Søholm H, Thomsen JH, Lippert FK, Møller JE, Køber L, Kjaergaard J. Post-hypothermia fever is associated with increased mortality after out-of-hospital cardiac arrest. *Resuscitation*. 2013; 84:1734–1740. [PubMed: 23917079]

71. Winters SA, Wolf KH, Kettinger SA, Seif EK, Jones JS, Bacon-Baguley T. Assessment of risk factors for post-rewarming “rebound hyperthermia” in cardiac arrest patients undergoing therapeutic hypothermia. *Resuscitation*. 2013; 84:1245–1249. [PubMed: 23567472]
72. Bohman LE, Levine JM. Fever and therapeutic normothermia in severe brain injury: an update. *Curr Opin Crit Care*. 2014; 20:182–188. [PubMed: 24553340]
73. Badjatia N. Hyperthermia and fever control in brain injury. *Crit Care Med*. 2009; 37(7 suppl):S250–S257. [PubMed: 19535955]
74. Longstreth WT Jr, Fahrenbruch CE, Olsufka M, Walsh TR, Copass MK, Cobb LA. Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. *Neurology*. 2002; 59:506–514. [PubMed: 12196641]
75. Rittenberger JC, Popescu A, Brenner RP, Guyette FX, Callaway CW. Frequency and timing of nonconvulsive status epilepticus in comatose post-cardiac arrest subjects treated with hypothermia. *Neurocrit Care*. 2012; 16:114–122. [PubMed: 21638118]
76. Tomte O, Draegni T, Mangschau A, Jacobsen D, Auestad B, Sunde K. A comparison of intravascular and surface cooling techniques in comatose cardiac arrest survivors. *Crit Care Med*. 2011; 39:443–449. [PubMed: 21169821]
77. Hofmeijer J, Tjepkema-Cloostermans MC, Blans MJ, Beishuizen A, van Putten MJ. Unstandardized treatment of electroencephalographic status epilepticus does not improve outcome of comatose patients after cardiac arrest. *Front Neurol*. 2014; 5:39. [PubMed: 24744748]
78. Crepeau AZ, Rabinstein AA, Fugate JE, Mandrekar J, Wijdicks EF, White RD, Britton JW. Continuous EEG in therapeutic hypothermia after cardiac arrest: prognostic and clinical value. *Neurology*. 2013; 80:339–344. [PubMed: 23284064]
79. Knight WA, Hart KW, Adeoye OM, Bonomo JB, Keegan SP, Ficker DM, Szaflarski JP, Privitera MD, Lindsell CJ. The incidence of seizures in patients undergoing therapeutic hypothermia after resuscitation from cardiac arrest. *Epilepsy Res*. 2013; 106:396–402. [PubMed: 23906560]
80. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. *Brain Resuscitation Clinical Trial I Study Group*. *N Engl J Med*. 1986; 314:397–403. [PubMed: 2868412]
81. Monsalve F, Rucabado L, Ruano M, Cuiñat J, Lacueva V, Viñuales A. The neurologic effects of thiopental therapy after cardiac arrest. *Intensive Care Med*. 1987; 13:244–248. [PubMed: 3301970]
82. Friedman D, Claassen J, Hirsch LJ. Continuous electroencephalogram monitoring in the intensive care unit. *Anesth Analg*. 2009; 109:506–523. [PubMed: 19608827]
83. Roberts BW, Kilgannon JH, Chansky ME, Mittal N, Wooden J, Trzeciak S. Association between postresuscitation partial pressure of arterial carbon dioxide and neurological outcome in patients with post-cardiac arrest syndrome. *Circulation*. 2013; 127:2107–2113. [PubMed: 23613256]
84. Lee BK, Jeung KW, Lee HY, Lee SJ, Jung YH, Lee WK, Heo T, Min YI. Association between mean arterial blood gas tension and outcome in cardiac arrest patients treated with therapeutic hypothermia. *Am J Emerg Med*. 2014; 32:55–60. [PubMed: 24210887]
85. Schneider AG, Eastwood GM, Bellomo R, Bailey M, Lipcsey M, Pilcher D, Young P, Stow P, Santamaria J, Stachowski E, Suzuki S, Woinarski NC, Pilcher J. Arterial carbon dioxide tension and outcome in patients admitted to the intensive care unit after cardiac arrest. *Resuscitation*. 2013; 84:927–934. [PubMed: 23454258]
86. Vaahersalo J, Bendel S, Reinikainen M, Kurola J, Tiainen M, Raj R, Pettilä V, Varpula T, Skrifvars MB. FINNRESUSCI Study Group. Arterial blood gas tensions after resuscitation from out-of-hospital cardiac arrest: associations with long-term neurologic outcome. *Crit Care Med*. 2014; 42:1463–1470. [PubMed: 24557423]
87. Janz DR, Hollenbeck RD, Pollock JS, McPherson JA, Rice TW. Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest. *Crit Care Med*. 2012; 40:3135–3139. [PubMed: 22971589]
88. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, Parrillo JE, Trzeciak S. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA*. 2010; 303:2165–2171. [PubMed: 20516417]

89. Elmer J, Scutella M, Pullalarevu R, Wang B, Vaghasia N, Trzeciak S, Rosario-Rivera BL, Guyette FX, Rittenberger JC, Dezfulian C. Pittsburgh Post-Cardiac Arrest Service (PCAS). The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database. *Intensive Care Med.* 2015; 41:49–57. [PubMed: 25472570]
90. Rachmale S, Li G, Wilson G, Malinchoc M, Gajic O. Practice of excessive F(IO(2)) and effect on pulmonary outcomes in mechanically ventilated patients with acute lung injury. *Respir Care.* 2012; 57:1887–1893. [PubMed: 22613692]
91. Bellomo R, Bailey M, Eastwood GM, Nichol A, Pilcher D, Hart GK, Reade MC, Egi M, Cooper DJ. Study of Oxygen in Critical Care (SOCC) Group. Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest. *Crit Care.* 2011; 15:R90. [PubMed: 21385416]
92. Nelskylä A, Parr MJ, Skrifvars MB. Prevalence and factors correlating with hyperoxia exposure following cardiac arrest—an observational single centre study. *Scand J Trauma Resusc Emerg Med.* 2013; 21:35. [PubMed: 23639102]
93. Kuisma M, Boyd J, Voipio V, Alaspää A, Roine RO, Rosenberg P. Comparison of 30 and the 100% inspired oxygen concentrations during early post-resuscitation period: a randomised controlled pilot study. *Resuscitation.* 2006; 69:199–206. [PubMed: 16500018]
94. Ihle JF, Bernard S, Bailey MJ, Pilcher DV, Smith K, Scheinkestel CD. Hyperoxia in the intensive care unit and outcome after out-of-hospital ventricular fibrillation cardiac arrest. *Crit Care Resusc.* 2013; 15:186–190. [PubMed: 23944204]
95. Oksanen T, Skrifvars MB, Varpula T, Kuitunen A, Pettilä V, Nurmi J, Castrén M. Strict versus moderate glucose control after resuscitation from ventricular fibrillation. *Intensive Care Med.* 2007; 33:2093–2100. [PubMed: 17928994]
96. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA.* 2008; 300:933–944. [PubMed: 18728267]
97. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. *Chest.* 2010; 137:544–551. [PubMed: 20018803]
98. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Diabetes Care.* 2009; 32:1119–1131. [PubMed: 19429873]
99. Sandroni C, Cariou A, Cavallaro F, Cronberg T, Friberg H, Hoedemaekers C, Horn J, Nolan JP, Rossetti AO, Soar J. Prognostication in comatose survivors of cardiac arrest: an advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine. *Resuscitation.* 2014; 85:1779–1789. [PubMed: 25438253]
100. Empey PE, de Mendizabal NV, Bell MJ, Bies RR, Anderson KB, Kochanek PM, Adelson PD, Poloyac SM. Pediatric TBI Consortium: Hypothermia Investigators. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. *Crit Care Med.* 2013; 41:2379–2387. [PubMed: 23896831]
101. Hostler D, Zhou J, Tortorici MA, Bies RR, Rittenberger JC, Empey PE, Kochanek PM, Callaway CW, Poloyac SM. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. *Drug Metab Dispos.* 2010; 38:781–788. [PubMed: 20164112]
102. Sandroni C, Cavallaro F, Callaway CW, Sanna T, D'Arrigo S, Kuiper M, Della Marca G, Nolan JP. Predictors of poor neurological outcome in adult comatose survivors of cardiac arrest: a systematic review and meta-analysis. Part 1: patients not treated with therapeutic hypothermia. *Resuscitation.* 2013; 84:1310–1323. [PubMed: 23811182]
103. Sandroni C, Cavallaro F, Callaway CW, D'Arrigo S, Sanna T, Kuiper MA, Biancone M, Della Marca G, Farcomeni A, Nolan JP. Predictors of poor neurological outcome in adult comatose survivors of cardiac arrest: a systematic review and meta-analysis. Part 2: Patients treated with therapeutic hypothermia. *Resuscitation.* 2013; 84:1324–1338. [PubMed: 23831242]
104. Bouwes A, Binnekade JM, Kuiper MA, Bosch FH, Zandstra DF, Toornvliet AC, Biemond HS, Kors BM, Koelman JH, Verbeek MM, Weinstein HC, Hijdra A, Horn J. Prognosis of coma after therapeutic hypothermia: a prospective cohort study. *Ann Neurol.* 2012; 71:206–212. [PubMed: 22367993]

105. Choi SP, Youn CS, Park KN, Wee JH, Park JH, Oh SH, Kim SH, Kim JY. Therapeutic hypothermia in adult cardiac arrest because of drowning. *Acta Anaesthesiol Scand*. 2012; 56:116–123. [PubMed: 22091986]
106. Cronberg T, Rundgren M, Westhall E, Englund E, Siemund R, Rosén I, Widner H, Friberg H. Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. *Neurology*. 2011; 77:623–630. [PubMed: 21775743]
107. Fugate JE, Wijdicks EF, Mandrekar J, Claassen DO, Manno EM, White RD, Bell MR, Rabinstein AA. Predictors of neurologic outcome in hypothermia after cardiac arrest. *Ann Neurol*. 2010; 68:907–914. [PubMed: 21061401]
108. Samaniego EA, Mlynash M, Caulfield AF, Eyingorn I, Wijman CA. Sedation confounds outcome prediction in cardiac arrest survivors treated with hypothermia. *Neurocrit Care*. 2011; 15:113–119. [PubMed: 20680517]
109. Bouwes A, van Poppelen D, Koelman JH, Kuiper MA, Zandstra DF, Weinstein HC, Tromp SC, Zandbergen EG, Tijssen MA, Horn J. Acute posthypoxic myoclonus after cardiopulmonary resuscitation. *BMC Neurol*. 2012; 12:63. [PubMed: 22853736]
110. Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. *Ann Neurol*. 2010; 67:301–307. [PubMed: 20373341]
111. Rossetti AO, Carrera E, Oddo M. Early EEG correlates of neuronal injury after brain anoxia. *Neurology*. 2012; 78:796–802. [PubMed: 22323758]
112. Bisschops LL, van Alfen N, Bons S, van der Hoeven JG, Hoedemaekers CW. Predictors of poor neurologic outcome in patients after cardiac arrest treated with hypothermia: a retrospective study. *Resuscitation*. 2011; 82:696–701. [PubMed: 21419561]
113. Bertini G, Margheri M, Giglioli C, Cricelli F, De Simone L, Taddei T, Marchionni N, Zini G, Gensini GF. Prognostic significance of early clinical manifestations in postanoxic coma: a retrospective study of 58 patients resuscitated after prehospital cardiac arrest. *Crit Care Med*. 1989; 17:627–633. [PubMed: 2736922]
114. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, de Haan RJ. PROPAC Study Group. Prediction of poor outcome within the first 3 days of postanoxic coma. *Neurology*. 2006; 66:62–68. [PubMed: 16401847]
115. Edgren E, Hedstrand U, Nordin M, Rydin E, Ronquist G. Prediction of outcome after cardiac arrest. *Crit Care Med*. 1987; 15:820–825. [PubMed: 3621954]
116. Young GB, Doig G, Ragazzoni A. Anoxic-ischemic encephalopathy: clinical and electrophysiological associations with outcome. *Neurocrit Care*. 2005; 2:159–164. [PubMed: 16159058]
117. Topcuoglu MA, Oguz KK, Buyukserbetci G, Bulut E. Prognostic value of magnetic resonance imaging in post-resuscitation encephalopathy. *Intern Med*. 2009; 48:1635–1645. [PubMed: 19755766]
118. Legriel S, Hilly-Ginoux J, Resche-Rigon M, Merceron S, Pinoteau J, Henry-Lagarigue M, Bruneel F, Nguyen A, Guezennec P, Troché G, Richard O, Pico F, Bédos JP. Prognostic value of electrographic postanoxic status epilepticus in comatose cardiac-arrest survivors in the therapeutic hypothermia era. *Resuscitation*. 2013; 84:343–350. [PubMed: 23146879]
119. Oddo M, Rossetti AO. Early multimodal outcome prediction after cardiac arrest in patients treated with hypothermia. *Crit Care Med*. 2014; 42:1340–1347. [PubMed: 24463859]
120. Deleted in proof.
121. Accardo J, De Lisi D, Lazzerini P, Primavera A. Good functional outcome after prolonged postanoxic comatose myoclonic status epilepticus in a patient who had undergone bone marrow transplantation. *Case Rep Neurol Med*. 2013; 2013:872127. [PubMed: 24368951]
122. Greer DM. Unexpected good recovery in a comatose post-cardiac arrest patient with poor prognostic features. *Resuscitation*. 2013; 84:e81–e82. [PubMed: 23454437]
123. Lucas JM, Cocchi MN, Saliccioli J, Stanbridge JA, Geocadin RG, Herman ST, Donnino MW. Neurologic recovery after therapeutic hypothermia in patients with post-cardiac arrest myoclonus. *Resuscitation*. 2012; 83:265–269. [PubMed: 21963817]
124. Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. *Ann Neurol*. 1994; 35:239–243. [PubMed: 8109907]

125. Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. *Neurology*. 1988; 38:401–405. [PubMed: 3347343]
126. Hirsch LJ, LaRoche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, Mani R, Arif H, Jette N, Minazad Y, Kerrigan JF, Vespa P, Hantus S, Claassen J, Young GB, So E, Kaplan PW, Nuwer MR, Fountain NB, Drislane FW. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version. *J Clin Neurophysiol*. 2013; 30:1–27. [PubMed: 23377439]
127. Kawai M, Thapalia U, Verma A. Outcome from therapeutic hypothermia and EEG. *J Clin Neurophysiol*. 2011; 28:483–488. [PubMed: 21946362]
128. Rundgren M, Westhall E, Cronberg T, Rosén I, Friberg H. Continuous amplitude-integrated electroencephalogram predicts outcome in hypothermia-treated cardiac arrest patients. *Crit Care Med*. 2010; 38:1838–1844. [PubMed: 20562694]
129. Cloostermans MC, van Meulen FB, Eertman CJ, Hom HW, van Putten MJ. Continuous electroencephalography monitoring for early prediction of neurological outcome in postanoxic patients after cardiac arrest: a prospective cohort study. *Crit Care Med*. 2012; 40:2867–2875. [PubMed: 22824933]
130. Mani R, Schmitt SE, Mazer M, Putt ME, Gaieski DF. The frequency and timing of epileptiform activity on continuous electroencephalogram in comatose post-cardiac arrest syndrome patients treated with therapeutic hypothermia. *Resuscitation*. 2012; 83:840–847. [PubMed: 22366352]
131. Legriél S, Bruneel F, Sediri H, Hilly J, Abbosh N, Lagarrigue MH, Troche G, Guezennec P, Pico F, Bedos JP. Early EEG monitoring for detecting postanoxic status epilepticus during therapeutic hypothermia: a pilot study. *Neurocrit Care*. 2009; 11:338–344. [PubMed: 19588273]
132. Wennervirta JE, Ermes MJ, Tiainen SM, Salmi TK, Hynninen MS, Särkelä MO, Hynninen MJ, Stenman UH, Viertiö-Oja HE, Saastamoinen KP, Pettilä VY, Vakkuri AP. Hypothermia-treated cardiac arrest patients with good neurological outcome differ early in quantitative variables of EEG suppression and epileptiform activity. *Crit Care Med*. 2009; 37:2427–2435. [PubMed: 19487928]
133. Stammet P, Wagner DR, Gilson G, Devaux Y. Modeling serum level of s100 $\beta$  and bispectral index to predict outcome after cardiac arrest. *J Am Coll Cardiol*. 2013; 62:851–858. [PubMed: 23684684]
134. Bassetti C, Bomio F, Mathis J, Hess CW. Early prognosis in coma after cardiac arrest: a prospective clinical, electrophysiological, and biochemical study of 60 patients. *J Neurol Neurosurg Psychiatry*. 1996; 61:610–615. [PubMed: 8971110]
135. Rothstein TL, Thomas EM, Sumi SM. Predicting outcome in hypoxicischemic coma. A prospective clinical and electrophysiologic study. *Electroencephalogr Clin Neurophysiol*. 1991; 79:101–107. [PubMed: 1713822]
136. Scollo-Lavizzari G, Bassetti C. Prognostic value of EEG in post-anoxic coma after cardiac arrest. *Eur Neurol*. 1987; 26:161–170. [PubMed: 3569370]
137. Bouwes A, Binnekade JM, Zandstra DF, Koelman JH, van Schaik IN, Hijdra A, Horn J. Somatosensory evoked potentials during mild hypothermia after cardiopulmonary resuscitation. *Neurology*. 2009; 73:1457–1461. [PubMed: 19884573]
138. Tiainen M, Kovala TT, Takkunen OS, Roine RO. Somatosensory and brainstem auditory evoked potentials in cardiac arrest patients treated with hypothermia. *Crit Care Med*. 2005; 33:1736–1740. [PubMed: 16096450]
139. Leithner C, Ploner CJ, Hasper D, Storm C. Does hypothermia influence the predictive value of bilateral absent N20 after cardiac arrest? *Neurology*. 2010; 74:965–969. [PubMed: 20308680]
140. Zanatta P, Messerotti Benvenuti S, Baldanzi F, Bosco E. Pain-related middle-latency somatosensory evoked potentials in the prognosis of post anoxic coma: a preliminary report. *Minerva Anesthesiol*. 2012; 78:749–756. [PubMed: 22337155]
141. Brunko E, Zegers de Beyl D. Prognostic value of early cortical somatosensory evoked potentials after resuscitation from cardiac arrest. *Electroencephalogr Clin Neurophysiol*. 1987; 66:15–24. [PubMed: 2431861]



142. Stelzl T, von Bose MJ, Hognl B, Fuchs HH, Flugel KA. A comparison of the prognostic value of neuron-specific enolase serum levels and somatosensory evoked potentials in 13 reanimated patients. *Eur J Emerg Med.* 1995; 2:24–27. [PubMed: 9422176]
143. Rothstein TL. The role of evoked potentials in anoxic-ischemic coma and severe brain trauma. *J Clin Neurophysiol.* 2000; 17:486–497. [PubMed: 11085552]
144. Berek K, Lechleitner P, Luef G, Felber S, Saltuari L, Schinnerl A, Traweger C, Dienstl F, Aichner F. Early determination of neurological outcome after prehospital cardiopulmonary resuscitation. *Stroke.* 1995; 26:543–549. [PubMed: 7709394]
145. Zandbergen EG, Koelman JH, de Haan RJ, Hijdra A. PROPAC-Study Group. SSEPs and prognosis in postanoxic coma: only short or also long latency responses? *Neurology.* 2006; 67:583–586. [PubMed: 16924008]
146. Madl C, Kramer L, Domanovits H, Woolard RH, Gervais H, Gendo A, Eisenhuber E, Grimm G, Sterz F. Improved outcome prediction in unconscious cardiac arrest survivors with sensory evoked potentials compared with clinical assessment. *Crit Care Med.* 2000; 28:721–726. [PubMed: 10752821]
147. Zingler VC, Krumm B, Bertsch T, Fassbender K, Pohlmann-Eden B. Early prediction of neurological outcome after cardiopulmonary resuscitation: a multimodal approach combining neurobiochemical and electrophysiological investigations may provide high prognostic certainty in patients after cardiac arrest. *Eur Neurol.* 2003; 49:79–84. [PubMed: 12584414]
148. Gendo A, Kramer L, Häfner M, Funk GC, Zauner C, Sterz F, Holzer M, Bauer E, Madl C. Time-dependency of sensory evoked potentials in comatose cardiac arrest survivors. *Intensive Care Med.* 2001; 27:1305–1311. [PubMed: 11511943]
149. Zhang Y, Su YY, Haupt WF, Zhao JW, Xiao SY, Li HL, Pang Y, Yang QL. Application of electrophysiologic techniques in poor outcome prediction among patients with severe focal and diffuse ischemic brain injury. *J Clin Neurophysiol.* 2011; 28:497–503. [PubMed: 21946368]
150. Kottenberg-Assemacher E, Armbruster W, Bornfeld N, Peters J. Hypothermia does not alter somatosensory evoked potential amplitude and global cerebral oxygen extraction during marked sodium nitroprusside-induced arterial hypotension. *Anesthesiology.* 2003; 98:1112–1118. [PubMed: 12717132]
151. Mlynash M, Campbell DM, Leproust EM, Fischbein NJ, Bammer R, Eyngorn I, Hsia AW, Moseley M, Wijman CA. Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest. *Stroke.* 2010; 41:1665–1672. [PubMed: 20595666]
152. Wijdicks EF, Campeau NG, Miller GM. MR imaging in comatose survivors of cardiac resuscitation. *AJNR Am J Neuroradiol.* 2001; 22:1561–1565. [PubMed: 11559506]
153. Inamasu J, Miyatake S, Suzuki M, Nakatsukasa M, Tomioka H, Honda M, Kase K, Kobayashi K. Early CT signs in out-of-hospital cardiac arrest survivors: Temporal profile and prognostic significance. *Resuscitation.* 2010; 81:534–538. [PubMed: 20189285]
154. Kim SH, Choi SP, Park KN, Youn CS, Oh SH, Choi SM. Early brain computed tomography findings are associated with outcome in patients treated with therapeutic hypothermia after out-of-hospital cardiac arrest. *Scand J Trauma Resusc Emerg Med.* 2013; 21:57. [PubMed: 23870424]
155. Lee BK, Jeung KW, Lee HY, Jung YH, Lee DH. Combining brain computed tomography and serum neuron specific enolase improves the prognostic performance compared to either alone in comatose cardiac arrest survivors treated with therapeutic hypothermia. *Resuscitation.* 2013; 84:1387–1392. [PubMed: 23792112]
156. Morimoto Y, Kemmotsu O, Kitami K, Matsubara I, Tedo I. Acute brain swelling after out-of-hospital cardiac arrest: pathogenesis and outcome. *Crit Care Med.* 1993; 21:104–110. [PubMed: 8420715]
157. Choi SP, Park HK, Park KN, Kim YM, Ahn KJ, Choi KH, Lee WJ, Jeong SK. The density ratio of grey to white matter on computed tomography as an early predictor of vegetative state or death after cardiac arrest. *Emerg Med J.* 2008; 25:666–669. [PubMed: 18843066]
158. Torbey MT, Geocadin R, Bhardwaj A. Brain arrest neurological outcome scale (BrANOS): predicting mortality and severe disability following cardiac arrest. *Resuscitation.* 2004; 63:55–63. [PubMed: 15451587]

159. Wijman CA, Mlynash M, Caulfield AF, Hsia AW, Eyngorn I, Bammer R, Fischbein N, Albers GW, Moseley M. Prognostic value of brain diffusion-weighted imaging after cardiac arrest. *Ann Neurol*. 2009; 65:394–402. [PubMed: 19399889]
160. Kim J, Choi BS, Kim K, Jung C, Lee JH, Jo YH, Rhee JE, Kim T, Kang KW. Prognostic performance of diffusion-weighted MRI combined with NSE in comatose cardiac arrest survivors treated with mild hypothermia. *Neurocrit Care*. 2012; 17:412–420. [PubMed: 22932993]
161. Els T, Kassubek J, Kubalek R, Klisch J. Diffusion-weighted MRI during early global cerebral hypoxia: a predictor for clinical outcome? *Acta Neurol Scand*. 2004; 110:361–367. [PubMed: 15527448]
162. Wu O, Sorensen AG, Benner T, Singhal AB, Furie KL, Greer DM. Comatose patients with cardiac arrest: predicting clinical outcome with diffusion-weighted MR imaging. *Radiology*. 2009; 252:173–181. [PubMed: 19420318]
163. Greer D, Scripko P, Bartscher J, Sims J, Camargo E, Singhal A, Parides M, Furie K. Clinical MRI interpretation for outcome prediction in cardiac arrest. *Neurocrit Care*. 2012; 17:240–244. [PubMed: 22565633]
164. Hachimi-Idrissi S, Van der Auwera M, Schiettecatte J, Ebinger G, Michotte Y, Huyghens L. S-100 protein as early predictor of regaining consciousness after out of hospital cardiac arrest. *Resuscitation*. 2002; 53:251–257. [PubMed: 12062839]
165. Rosén H, Rosengren L, Herlitz J, Blomstrand C. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. *Stroke*. 1998; 29:473–477. [PubMed: 9472892]
166. Steffen IG, Hasper D, Ploner CJ, Schefold JC, Dietz E, Martens F, Nee J, Krueger A, Jörres A, Storm C. Mild therapeutic hypothermia alters neuron specific enolase as an outcome predictor after resuscitation: 97 prospective hypothermia patients compared to 133 historical non-hypothermia patients. *Crit Care*. 2010; 14:R69. [PubMed: 20403168]
167. Reisinger J, Höllinger K, Lang W, Steiner C, Winter T, Zeindlhofer E, Mori M, Schiller A, Lindorfer A, Wiesinger K, Siostrzonek P. Prediction of neurological outcome after cardiopulmonary resuscitation by serial determination of serum neuron-specific enolase. *Eur Heart J*. 2007; 28:52–58. [PubMed: 17060343]
168. Tiainen M, Roine RO, Pettilä V, Takkunen O. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. *Stroke*. 2003; 34:2881–2886. [PubMed: 14631087]
169. Rosén H, Sunnerhagen KS, Herlitz J, Blomstrand C, Rosengren L. Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. *Resuscitation*. 2001; 49:183–191. [PubMed: 11382525]
170. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, Jochum M. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. *Crit Care Med*. 2002; 30:2669–2674. [PubMed: 12483057]
171. Mörtberg E, Zetterberg H, Nordmark J, Blennow K, Rosengren L, Rubertsson S. S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment. *Resuscitation*. 2011; 82:26–31. [PubMed: 21071131]
172. Huntgeburth M, Adler C, Rosenkranz S, Zobel C, Haupt WF, Dohmen C, Reuter H. Changes in neuron-specific enolase are more suitable than its absolute serum levels for the prediction of neurologic outcome in hypothermia-treated patients with out-of-hospital cardiac arrest. *Neurocrit Care*. 2014; 20:358–366. [PubMed: 23836424]
173. Oksanen T, Tiainen M, Skrifvars MB, Varpula T, Kuitunen A, Castrén M, Pettilä V. Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. *Resuscitation*. 2009; 80:165–170. [PubMed: 18954930]
174. Rundgren M, Karlsson T, Nielsen N, Cronberg T, Johnsson P, Friberg H. Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia. *Resuscitation*. 2009; 80:784–789. [PubMed: 19467754]

175. Storm C, Nee J, Jörres A, Leithner C, Hasper D, Ploner CJ. Serial measurement of neuron specific enolase improves prognostication in cardiac arrest patients treated with hypothermia: a prospective study. *Scand J Trauma Resusc Emerg Med.* 2012; 20:6. [PubMed: 22284447]
176. Zellner T, Gärtner R, Schopohl J, Angstwurm M. NSE and S-100B are not sufficiently predictive of neurologic outcome after therapeutic hypothermia for cardiac arrest. *Resuscitation.* 2013; 84:1382–1386. [PubMed: 23528678]
177. Orioles A, Morrison WE, Rossano JW, Shore PM, Hasz RD, Martiner AC, Berg RA, Nadkarni VM. An under-recognized benefit of cardiopulmonary resuscitation: organ transplantation. *Crit Care Med.* 2013; 41:2794–2799. [PubMed: 23949474]
178. Faucher A, Savary D, Jund J, Dorez D, Debatty G, Gaillard A, Atchabahian A, Tazarourte K. Out-of-hospital traumatic cardiac arrest: an underrecognized source of organ donors. *Transpl Int.* 2014; 27:42–48. [PubMed: 24118355]
179. Adrie C, Haouache H, Saleh M, Memain N, Laurent I, Thuong M, Darques L, Guerrini P, Monchi M. An underrecognized source of organ donors: patients with brain death after successfully resuscitated cardiac arrest. *Intensive Care Med.* 2008; 34:132–137. [PubMed: 17932649]
180. Ali AA, Lim E, Thanikachalam M, Sudarshan C, White P, Parameshwar J, Dhital K, Large SR. Cardiac arrest in the organ donor does not negatively influence recipient survival after heart transplantation. *Eur J Cardiothorac Surg.* 2007; 31:929–933. [PubMed: 17387020]
181. Hsu RB, Chu SH, Chien CY, Chou NK, Chen YS, Ko WJ, Wang SS. Heart transplantation with marginal recipients and donors. *J Formos Med Assoc.* 1999; 98:663–667. [PubMed: 10575834]
182. Quader MA, Wolfe LG, Kasirajan V. Heart transplantation outcomes from cardiac arrest-resuscitated donors. *J Heart Lung Transplant.* 2013; 32:1090–1095. [PubMed: 23994219]
183. Pilarczyk K, Osswald BR, Pizanis N, Tsagakis K, Massoudy P, Heckmann J, Jakob HG, Kamler M. Use of donors who have suffered cardiopulmonary arrest and resuscitation in lung transplantation. *Eur J Cardiothorac Surg.* 2011; 39:342–347. [PubMed: 21256043]
184. Sánchez-Lázaro IJ, Almenar-Bonet L, Martínez-Dolz L, Buendía-Fuentes F, Agüero J, Navarro-Manchón J, Raso-Raso R, Salvador-Sanz A. Can we accept donors who have suffered a resuscitated cardiac arrest? *Transplant Proc.* 2010; 42:3091–3092. [PubMed: 20970616]
185. Southerland KW, Castleberry AW, Williams JB, Daneshmand MA, Ali AA, Milano CA. Impact of donor cardiac arrest on heart transplantation. *Surgery.* 2013; 154:312–319. [PubMed: 23889957]
186. Conway J, Chin C, Kemna M, Burch M, Barnes A, Tresler M, Scheel JN, Naftel DC, Beddow K, Allain-Rooney T, Dipchand AI. Pediatric Heart Transplant Study Investigators. Donors' characteristics and impact on outcomes in pediatric heart transplant recipients. *Pediatr Transplant.* 2013; 17:774–781. [PubMed: 24102961]
187. de Begona JA, Gundry SR, Razzouk AJ, Boucek MM, Kawauchi M, Bailey LL. Transplantation of hearts after arrest and resuscitation. Early and long-term results. *J Thorac Cardiovasc Surg.* 1993; 106:1196–1201. discussion 1200. [PubMed: 8246560]
188. Finfer S, Bohn D, Colpitts D, Cox P, Fleming F, Barker G. Intensive care management of paediatric organ donors and its effect on post-transplant organ function. *Intensive Care Med.* 1996; 22:1424–1432. [PubMed: 8986499]
189. L'Ecuyer T, Sloan K, Tang L. Impact of donor cardiopulmonary resuscitation on pediatric heart transplant outcome. *Pediatr Transplant.* 2011; 15:742–745. [PubMed: 21883750]
190. Castleberry AW, Worni M, Osho AA, Snyder LD, Palmer SM, Pietrobon R, Davis RD, Hartwig MG. Use of lung allografts from brain-dead donors after cardiopulmonary arrest and resuscitation. *Am J Respir Crit Care Med.* 2013; 188:466–473. [PubMed: 23777361]
191. Mercatello A, Roy P, Ng-Sing K, Choux C, Baude C, Garnier JL, Colpart JJ, Finaz J, Petit P, Moskovtchenko JF. Organ transplants from out-of-hospital cardiac arrest patients. *Transplant Proc.* 1988; 20:749–750. [PubMed: 3188183]
192. Matsumoto CS, Kaufman SS, Girlanda R, Little CM, Rekhman Y, Raofi V, Laurin JM, Shetty K, Fennelly EM, Johnson LB, Fishbein TM. Utilization of donors who have suffered cardiopulmonary arrest and resuscitation in intestinal transplantation. *Transplantation.* 2008; 86:941–946. [PubMed: 18852660]

193. Fondevila C, Hessheimer AJ, Flores E, Ruiz A, Mestres N, Calatayud D, Paredes D, Rodríguez C, Fuster J, Navasa M, Rimola A, Taurá P, García-Valdecasas JC. Applicability and results of Maastricht type 2 donation after cardiac death liver transplantation. *Am J Transplant*. 2012; 12:162–170. [PubMed: 22070538]
194. Mateos-Rodríguez AA, Navalpotro-Pascual JM, Del Rio Gallegos F, Andrés-Belmonte A. Out-hospital donors after cardiac death in Madrid, Spain: a 5-year review. *Australas Emerg Nurs J*. 2012; 15:164–169. [PubMed: 22947689]
195. Alonso A, Fernández-Rivera C, Villaverde P, Oliver J, Cillero S, Lorenzo D, Valdés F. Renal transplantation from non-heart-beating donors: a single-center 10-year experience. *Transplant Proc*. 2005; 37:3658–3660. [PubMed: 16386496]
196. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Bronsther O, Randhawa P, Broznick B, Fung JJ, Starzl T. Experience with liver and kidney allografts from non-heart-beating donors. *Transplantation*. 1995; 59:197–203. [PubMed: 7839441]
197. Nicholson ML, Metcalfe MS, White SA, Waller JR, Doughman TM, Horsburgh T, Feehally J, Carr SJ, Veitch PS. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. *Kidney Int*. 2000; 58:2585–2591. [PubMed: 11115095]
198. Otero A, Gómez-Gutiérrez M, Suárez F, Arnal F, Fernández-García A, Aguirrezabalaga J, García-Buitrón J, Alvarez J, Mániz R. Liver transplantation from maastricht category 2 non-heart-beating donors: a source to increase the donor pool? *Transplant Proc*. 2004; 36:747–750. [PubMed: 15110650]